



# National Essential Medicine List 2025



Maldives Food and Drug Authority  
Medicine and Therapeutic Goods Division  
Ministry of Health  
Republic of Maldives

## Foreword by the Acting Director General



Essential medicines are defined as those that satisfy the priority health care needs of the population. These medicines are selected based on evidence of their efficacy, safety, and cost-effectiveness, and they represent the cornerstone of any well-functioning health system. Every individual, regardless of where they live or their socio-economic status, should have continuous access to these medicines in adequate quantities, appropriate dosage forms, and at affordable prices.

In the Maldives, the importance of an Essential Medicines List (EML) cannot be overstated. As a country that relies entirely on the importation of pharmaceuticals, we face unique challenges in maintaining a continuous supply of medicines. These challenges include fluctuations in global supply chains, pricing pressures, and logistical constraints. In this context, the EML serves as a vital tool to ensure that the most needed medicines are prioritized, procured, and made consistently available to the population. It also guides rational prescribing and helps prevent the irrational use of drugs, particularly antibiotics, thereby contributing to the global effort to combat antimicrobial resistance.

The EML is more than just a list; it is a strategic policy instrument. It informs decisions on medicine procurement, supports the allocation of financial and technical resources, and ensures consistency in prescribing practices across different levels of the health care system. Importers and suppliers are required to register and maintain stocks of essential medicines, which not only guarantees access but also promotes transparency, accountability, and quality assurance within the national pharmaceutical supply chain.

The successful implementation of the Essential Medicines List requires the collaboration of many stakeholders. In particular, the roles of importers, pharmacies, and healthcare providers are crucial.

in ensuring that essential medicines are continuously available and used rationally. I want to take this opportunity to sincerely thank the Core Committee for their invaluable oversight, expertise, and technical guidance in revising this publication. Their contributions have been central to aligning the list with the current health care needs of the Maldivian people.

I also extend my deepest gratitude to the dedicated team at the Maldives Food and Drug Authority (MFDA) for their tireless commitment to finalizing this updated edition of the Essential Medicines List. Their professionalism and dedication have ensured that this document reflects the highest standards of quality and relevance.

It is my firm conviction that this revised Essential Medicines List will play a crucial role in further strengthening the Maldivian healthcare system. Ensuring equitable access to safe, effective, and affordable medicines will support the delivery of patient-centered health care and contribute to the broader national vision of achieving universal health coverage. Furthermore, it will provide reassurance to the Maldivian people that their health needs remain a national priority and that adequate measures are in place to protect their well-being.

I am confident that this publication will serve as a valuable reference for policymakers, health care providers, importers, and all stakeholders engaged in improving access to medicines. I hope that this list will not only guide present health care decisions but also serve as a foundation for continued progress in ensuring the right to health for every citizen of the Maldives.

Thank you.



Ms. Thooma Adam  
*Acting Director General*

## Introduction

The National Essential Medicines List (NEML) serves as a fundamental document identifying a core set of medicines that address the priority health care needs of much of the Maldivian population. Its primary objective is to ensure that essential medicines are consistently accessible, available in appropriate dosage forms and quantities, of assured quality, and affordable for individuals and communities nationwide.

The NEML further aims to promote equity in health care by safeguarding access to essential medicines for all, while also guiding the rational selection, procurement, and use of medicines at every level of the health system. By standardizing the availability of safe, effective, and cost-efficient medicines, the NEML plays a critical role in strengthening the national pharmaceutical supply chain, preventing irrational prescribing, and supporting sustainable health financing.

Adapted from the World Health Organization (WHO) Model List of Essential Medicines, the Maldivian NEML has been contextualized to reflect the specific health care priorities, disease patterns, and population needs of the country. It also serves as a guiding framework for health facilities in formulating their own facility-level essential medicines lists, thereby ensuring alignment with national priorities while addressing local service delivery requirements.

The Essential Medicines List (EML) 2025 represents the latest revision following the earlier 2023 version. This updated list is the outcome of a rigorous review process, incorporating proposals and recommendations from various clinical departments, public health programs, and expert committees. It reflects the evolving health care needs of the Maldivian population across the continuum of care—from primary health care centers to tertiary and specialist facilities.

Furthermore, the 2025 EML accommodates the requirements of national health programs by including medicines essential for disease prevention, control, and treatment in priority public health areas. By ensuring the inclusion of evidence-based, cost-effective medicines, the EML supports the Ministry of Health's commitment to universal health coverage and the delivery of high-quality, patient-centered care.

## History and importance of essential medicines

The concept of essential medicines was first introduced by the World Health Organization (WHO) in 1977. Since then, it has been widely adopted and implemented by many countries, non-governmental organizations, and international non-profit supply agencies. The essential medicines list (EML) comprises a carefully selected range of the most effective and safe medicines for priority health conditions, chosen according to the health care needs of most of the population.

This deliberate and evidence-based selection of a limited number of medicines contributes significantly to improving the quality of medical care, enhancing the efficiency of medicine administration, and ensuring a more cost-effective allocation of scarce health resources. The EML concept is now globally recognized as one of the most critical public health milestones, particularly in advancing universal access to essential health services. By guaranteeing equitable access to the most needed medicines, it has played a transformative role in both developed and developing countries. To date, more than 160 countries have adopted the essential medicines concept, using national EMLs as the cornerstone for medicine supply systems, reimbursement mechanisms, and prescribing practices within their health systems.

The EML provides strategic direction in a wide range of areas, including hospital drug policies, public medicine procurement and supply, reimbursement under national health insurance schemes, and the management of medicine donations. It also serves as an essential reference for pharmaceutical quantification, cost estimation, and pricing. At the clinical level, the EML guides rational prescribing, ensuring that patients receive medicines that are both appropriate and effective. The integration of EML into health systems is therefore expected not only to improve prescribing practices but also to enhance access to medicines, strengthen the overall quality of health services, and ultimately improve health outcomes. Moreover, the consistent application of the EML framework supports the rational use of medicines, particularly antibiotics, thereby reducing inappropriate use and lowering the risk of antimicrobial resistance, which remains a major global health threat.

In the Maldives, the Essential Medicines List was first introduced in 2009 as part of a national effort to align medicine use with public health priorities. Since its initial development, the list

has undergone several systematic revisions in 2013, 2016, 2018, 2021, and 2023—to reflect changing disease patterns, evolving health care needs, and the introduction of new medicines, particularly those required for national health programs. Each revision process has been consultative, drawing on expertise from various clinical disciplines, regulatory bodies, and public health stakeholders to ensure that the list remains relevant and responsive to the population's needs.

The Essential Medicines List 2025 (EML 2025) represents the most recent update. It includes medicines that meet the current health care needs of the Maldivian population, spanning primary health care to specialist and tertiary services. The Maldives Food and Drug Authority (MFDA) is responsible for ensuring that the medicines included in the list are of assured quality, safe, and effective. At the same time, the Ministry of Health is responsible for ensuring their timely availability and affordability. This oversight is vital to safeguarding the credibility of the list and ensuring that the included medicines contribute meaningfully to improved health outcomes for the Maldivian people.

By continuing to update and strengthen the national EML, the Maldives reaffirms its commitment to promoting rational use of medicines, supporting equitable access to essential health care, and contributing to the broader global goal of achieving universal health coverage (UHC).

## Revision process for EML 2023 & members of the revision core committee and specialists who assisted in revising the EML

The revision of the Essential Medicines List (EML) 2025 was carried out by a core committee appointed by the Maldives Food and Drug Authority. The committee comprised members from the National Pharmaceutical Board as well as representatives from referral hospitals.

The committee evaluated proposals for additions and deletions to the EML 2025, which referral hospitals and the Ministry of Health submitted. Established criteria, including medicine safety,

clinical efficacy, affordability, suitability within the healthcare system, and availability in the Maldives, guided the review process.

As a result of the review, fifty-four (54) medicines were recommended for inclusion, primarily based on requests from tertiary hospitals where these medicines are frequently used and considered essential for hospital settings. Additionally, nineteen (19) medicines were recommended for deletion, as they are no longer in use and have been replaced by newly added alternatives.

The committee, with the support of the Secretariat, worked collaboratively throughout the process of finalizing the EML.

The committee includes:

Name	Designation	Organization
Dr. Hawwa Hana	Member of the National Pharmaceutical Board Senior Consultant Specialist in Obstetrics and Gynecology	Indhira Gandhi Memorial Hospital
Dr. Aishath Eleena	Member of the National Pharmaceutical Board Senior Consultant Sub Specialist in Pediatric Cardiology / HOD	Indhira Gandhi Memorial Hospital
Dr. Hiyaan Habeeb	Member of the National Pharmaceutical Board Consultant Specialist in Medicine	Indhira Gandhi Memorial Hospital
Dr. Mariyam Jenyfa	Member of the National Pharmaceutical Board Medical Officer	Health Protection Agency
Dr. Ahmed Ashraf	Member of the National Pharmaceutical Board Director General of Health Services	Ministry Of Health
Dr. Abdulla Niyaf	Chief Medical Officer, HOD & Senior Consultant in Pediatrics, Dive Medical & Hyperbaric	ADK Hospital
Dr. Nuzha Mohamed	Senior Consultant in Dermatology	ADK Hospital
Dr. Shifla Abdul Latheef	Consultant in Pediatrics	Senehiya Medical Hospital
Dr. Alessandra Maria Martino	Senior Pediatric Consultant / HOD	Tree Top Hospital

Furthermore, specialists from IGMH, ADK Hospital, Treetop Hospital, Hulhumale Hospital, and Senehiya Military Hospital provided valuable contributions to the finalization of the EML.

Name	Designation	Organization
Dr. Mohamed Mishwaar Ashfaq	Senior Consultant in Orthopaedics	ADK Hospital
Dr. Mariyam Yoomy	Consultant Specialist in Orthopaedics	Indhira Gandhi Memorial Hospital
Dr. Shaneez Najmy	Consultant Sub-Specialist in Cardiology	Indhira Gandhi Memorial Hospital
Dr. Arif Mohamed	Consultant Sub-Specialist in Psychiatry	Indhira Gandhi Memorial Hospital
Dr. Haikal Abdul Rahman	Senior Consultant, Specialist in Dermatology	Indhira Gandhi Memorial Hospital
Dr. Mohamed Shaafiee	Registrar	Maldives Medical and Dental Council
Dr. Aminath Munaza	Internal Medicine	Hulhumale Hospital
Dr. Ravi Kanodia	Consultant in Oncology	ADK Hospital
Dr. Mohamed Amru Ahmed	Consultant in Oncology	Indhira Gandhi Memorial Hospital
Dr. Ahmed Saif	Consultant in Endocrinology	ADK Hospital
Dr. Mohamed Siruhan	Consultant Sub-Specialist in Endocrinology	Indhira Gandhi Memorial Hospital
Dr. Aishath Jeneena Amir	Consultant in Ophthalmology	ADK Hospital
Dr. Mariyam Shahana Mufeed	Consultant Specialist in Ophthalmology	Indhira Gandhi Memorial Hospital
Dr. Nadeema Rasheed	Consultant in Orthodontics	Indhira Gandhi Memorial Hospital
Uz. Thasleema Usman	Commissioner of Quality Assurance	Ministry Of Health
Dr. Ahmed Fahud	Medical Officer-Non-Clinical	Ministry Of Health
Dr. Mariyam Aseela	Senior Healthcare Quality Assurance Officer	Ministry Of Health
Dr. Ilham Shareef	Consultant in Dentistry	Tree Top Hospital
Dr. Soodh Antony	Senior Registrar in Dentistry	ADK Hospital
Dr. Praveen Jeya Chidambara Pandian	Dentist HOD	ADK Hospital
Dr. Aishath Reema	Senior Consultant, specialist in Dermatology	Indhira Gandhi Memorial Hospital

The designated staff of the Medicine and Therapeutic Goods Division of the Maldives Food and Drug Authority, who were nominated as the Secretariat, Mr. Mohamed Fazeen (Director, Pharmaceuticals) and Ms. Fathimath Azla (Medicine Regulatory Officer), have worked diligently throughout to achieve the goal.



The categorization system presented in the EML is designed to ensure equitable and efficient access to essential medicines across all levels of the healthcare system in the Maldives.

## Dosage forms

The main terms used for dosage forms in the Essential Medicines List are detailed below with reference to the WHO Model List of Essential Medicines

### A. Principal dosage forms used in EML – Oral administration

Term	Definition
<b>Solid oral dosage form</b>	Refers to tablets, capsules, or other solid dosage forms such as 'melts' that are immediate-release preparations. It implies that there is no difference in clinical efficacy or safety between the available dosage forms, and countries should therefore choose the form(s) to be listed depending on quality and availability. The term 'solid oral dosage form' is <i>never</i> intended to allow any modified-release tablet.
<b>Tablets</b>	Refers to: Uncoated or coated (film-coated or sugar-coated) tablets that are intended to be swallowed whole; Un-scored and scored*; Tablets that are intended to be chewed before being swallowed; Tablets that are intended to be dispersed or dissolved in water or another suitable liquid before being swallowed; Tablets that are intended to be crushed before being swallowed.  The term 'tablet' without qualification is <i>never</i> intended to allow any modified-release tablet.
<b>Tablets (qualified)</b>	Refers to a specific type of <b>Tablet</b> : chewable - tablets that are intended to be chewed before being swallowed; dispersible - tablets that are designed to be dispersed in water or another suitable liquid before being swallowed; soluble - tablets that are designed to be dissolved in water or another suitable liquid before being swallowed; crushable - tablets that are designed to be crushed before being swallowed; Scored - tablets bearing a break mark or marks where sub-division is intended to provide doses of less than one tablet; Sublingual - tablets that are intended to be placed beneath the tongue.  The term 'tablet' is <i>always</i> qualified with an additional term (in parentheses) in entries where one of the following types of tablets is intended: gastro-resistant (such tablets may sometimes be described as enteric-coated or as delayed-release), prolonged-release, or another modified-release form.

<b>Capsules</b>	Refers to hard or soft capsules. The term 'capsule' without qualification is <i>never</i> intended to allow any modified-release capsule.
<b>Capsules (qualified)</b>	The term 'capsule' with qualification refers to gastro-resistant (such capsules may sometimes be described as enteric-coated or as delayed-release), prolonged-release, or another modified-release form.
<b>Granules</b>	Preparations that are issued to patients as granules to be swallowed without further preparation, to be chewed, or to be taken with water or another suitable liquid. The term 'granules' without further qualification is <i>never</i> intended to allow any modified-release granules.
<b>Oral powder</b>	Preparations that are issued to patients as powder (usually as a single dose) to be taken with water or another suitable liquid.
<b>Oral liquid</b>	Liquid preparations intended for oral administration, i.e., oral solutions, suspensions, emulsions, and oral drops, including those constituted from powders or granules, but excluding preparations intended for oral mucosal administration, such as gargles and mouthwashes. Oral liquids presented as powders or granules may offer benefits, including improved stability and reduced transportation costs. Suppose more than one type of oral liquid is available on the same market (e.g., solution, suspension, granules for reconstitution). In that case, they may be interchanged, and in such cases, they should be bioequivalent. It is preferable that oral liquids do not contain sugar and that solutions for children do not contain alcohol.

## B. Principal dosage forms used in EML – parenteral administration

Term	Definition
<b>Injection</b>	Refers to solutions, suspensions, and emulsions, including those constituted from powders or concentrated solutions.
<b>Injection (qualified)</b>	Route of administration is indicated in parentheses where relevant.
<b>Injection (oily)</b>	The term 'injection' is qualified by '(oily)' in relevant entries.
<b>Intravenous infusion</b>	Refers to solutions and emulsions, including those constituted from powders or concentrated solutions.

## List of Essential Medicines 2025 (Categorization)

<b>P, S, T</b>	Stands for Primary, Secondary, and Tertiary levels of care
<b>S, T</b>	Stands for the Tertiary and Secondary levels of care
<b>T</b>	Stands for the Tertiary level of care
<b>NP</b>	Stands for Public Health National Programs

## List of Essential Medicines List 2025 – Schedules

Acronym	Expansion	Remarks
<b>Restricted for Health Facilities</b>	Medicines are restricted to special expertise and Health facilities and clinics with registered medical practitioners.	These are the medicines that can only be imported by MFDA-designated importers. These products cannot be sold in pharmacies.  <b>All the "Restricted for Hospital use/institutional use only" medicines are in dark blue text</b>
<b>Restricted to the National programs only</b>	Restricted for use in national programs only (e.g., Filariasis, Leprosy, Malaria, TB, HIV, EPI, Reproductive Health Programs, etc.)	These medicines can only be imported for use by the National Programs upon a valid request from the relevant agency.  <b>All the "Restricted and to be used for the National program only" medicines are in dark red text</b>
<b>Controlled</b>	Controlled Drugs, which include Narcotics and Psychotropics (Internationally and Nationally Controlled).	These are medicines that are controlled and can only be imported by designated parties. From these medicines, Narcotics cannot be kept in pharmacies for sale.  <b>All the "Controlled" medicines are in purple text.</b>
<b>OTC</b>	Over-the-counter medicine	These are the medicines that can be sold without prescriptions.  <b>All the "OTC" drugs are in blue text.</b>
<b>POM</b>	Prescription-only medicine	These are medicines that can be sold with a valid prescription.  <b>All the "POM" drugs are in black text.</b>

## List of Essential Medicines 2025

No.	Medicine / Product	Dosage Form and Strengths	Level of Care	Schedules
<b>1</b>	<b>ANAESTHETICS, PREOPERATIVE MEDICINES AND MEDICAL GASES</b>			
<b>1.1</b>	<b>General Anesthetics and Oxygen</b>			
	Halothane	<b>Inhalation.</b>	S, T	Restricted for Health Facilities
	Isoflurane	<b>Inhalation.</b>	S, T	Restricted for Health Facilities
	Ketamine	<b>Injection:</b> 50mg/mL in 10 mL vial; 10mg/mL	S, T	Controlled + Hospital use only
	Nitrous oxide	<b>Inhalation.</b>	S, T	Restricted for Health Facilities
	Propofol	<b>Injection:</b> 10mg/mL, 20 mg/mL	S, T	Restricted for Health Facilities
	Chloral hydrate	<b>Syrup:</b> 250 mg/5mL	S, T	Restricted for Health Facilities
	Oxygen	<b>Inhalation</b> (medical gas)	P, S, T	<b>POM</b>
	Medical air	<b>Inhalation</b> (medical gas)	P, S, T	Restricted for Health Facilities
<b>1.2</b>	<b>Local anaesthetics</b>			
	Lidocaine	<b>Injection for spinal anaesthesia:</b> 5% [HCl] in a 2 mL ampoule to be mixed with 7.5 % glucose <b>Injection:</b> 1%, 2% (HCl) in vial <b>Topical forms:</b> 2% – 4 % [HCl]; 10 % topical spray	S, T	Restricted for Health Facilities
	Lidocaine + epinephrine [adrenaline]	<b>Injection:</b> 1%, 2% (HCl) + epinephrine 1:200,000 in a vial. <b>Dental cartridge:</b> 2 % [HCl] + epinephrine 1:80,000.	S, T	Restricted for Health Facilities
	Bupivacaine	<b>Injection for spinal anaesthesia:</b> 0.5 % [HCl] in a 4 mL ampoule to be mixed with 7.5 % glucose solution. <b>Injection:</b> 0.25 %, 0.5 % [HCl] in vial.	S, T	Restricted for Health Facilities
	Ephedrine	<b>Injection:</b> 30 mg/ml [HCl] in 1 mL ampoule	S, T	Controlled + for Hospital use only
<b>1.3</b>	<b>Preoperative medication and sedation for short-term procedures</b>			
	Atropine	<b>Injection:</b> 0.6 mg in 1 mL ampoule, 1mg (sulphate) in 1ml ampoule	P, S, T	Restricted for Health Facilities
	Fentanyl	<b>Injection:</b> 50 mcg/mL in 2–mL ampoule <b>Oral Liquid:</b> 2 mg/5 mL <b>Tablet:</b> 2 mg; 5 mg	S, T	Controlled
	Morphine sulphate	<b>Tablet:</b> 10mg; 15 mg; 30 mg <b>Syrup:</b> 10mg/5mL <b>Injection:</b> 10mg in 1 mL - ampoule	S, T	Controlled

	Midazolam	<b>Injection:</b> 5 mg/mL in 2 mL ampoule [HCl] <b>Nasal spray:</b> 5 mg/0.1 mL	S, T	Controlled
	Esmolol	<b>Injection:</b> 10 mg/mL	S, T	Restricted for Health Facilities
<b>2</b>	<b>MEDICINES FOR PAIN AND PALLIATIVE CARE</b>			
<b>2.1</b>	<b>Non opioids and non-steroidal anti-inflammatory medicines (NSAIDs)</b>			
	Ibuprofen	<b>Oral liquid:</b> 100 mg/5 mL <b>Tablet:</b> 200 mg; 400 mg <b>Injection:</b> 5mg/ml	P, S, T	<b>POM</b> <b>OTC</b> <b>POM</b>
	Paracetamol	<b>Tablet:</b> 500 mg <b>Oral liquid:</b> 120 mg/5 mL; 250 mg/5 mL <b>Oral Drops:</b> 100 mg/mL <b>Suppository:</b> 125 mg; 250 mg <b>Injection:</b> 100 mg/mL, 150 mg/mL	P, S, T	<b>OTC</b>   <b>POM</b>
	Diclofenac sodium	<b>Tablet:</b> 25 mg; 50 mg <b>Suppository:</b> 12.5 mg; 50 mg <b>Injection:</b> 75mg/ml	P, S, T	<b>POM</b> <b>POM</b> <b>POM</b>
	Mefenamic acid	<b>Tablet:</b> 250 mg; 500 mg	P, S, T	<b>OTC</b>
<b>2.2</b>	<b>Opioid analgesics</b>			
	Morphine sulphate	<b>Injection:</b> 10mg [sulphate of HCl] in 1 mL ampoule. <b>Oral liquid:</b> 10mg [sulphate or HCl]/5 mL <b>Tablet:</b> 5mg, 10mg	S, T	Controlled
	Tramadol	<b>Injection:</b> 50 mg/mL <b>Capsule:</b> 50 mg <b>Tablet:</b> 50 mg, 100mg (ER) <b>Oral Liquid:</b> 10mg/ml	P, S, T	<b>CONTROLLED</b>
	Pethidine	<b>Injection:</b> 50 mg/mL [ HCl]	P, S, T	<b>CONTROLLED</b>
<b>2.3</b>	<b>Medicines used to treat Gout</b>			
	Allopurinol	Tablet: 100 mg	S, T	<b>POM</b>
<b>2.4</b>	<b>Disease-modifying agents used in rheumatoid disorders.</b>			
	Methotrexate	<b>Tablet:</b> 2.5 mg; 5 mg; 7.5 mg; 10mg  <b>Injection:</b> 50mg/2mL, 250mg/10mL <b>Powder for Injection:</b> 50mg	S, T	<b>POM</b>  Restricted for Health Facilities
	Hydroxychloroquine phosphate	<b>Tablet:</b> 200 mg	T	<b>POM</b>
	Sulfasalazine	<b>Tablet:</b> 500 mg	S, T	<b>POM</b>
<b>3</b>	<b>ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS</b>			
	Cetirizine	<b>Oral liquid:</b> 5 mg/5 mL <b>Tablet:</b> 10mg	P, S, T	<b>OTC</b>
	Chlorpheniramine maleate	<b>Injection:</b> 10mg [ hydrogen maleate] in 1 mL ampoule; <b>Oral liquid:</b> 2 mg/5 mL; <b>Tablet:</b> 4 mg [hydrogen maleate]	P, S, T	<b>POM</b>

	Dexamethasone	<b>Injection:</b> 4 mg dexamethasone phosphate [as disodium salt] in 1 mL-ampoule <b>Tablet:</b> 0.5mg	P, S, T	<b>POM</b>
	Hydrocortisone	Powder for injection 100 mg [as sodium succinate] in a vial <b>Topical:</b> 0.5%, 1% <b>Tablet:</b> 5mg, 10mg	P, S, T	<b>POM</b>
	Prednisolone	<b>Tablet:</b> 5 mg; 10mg; 20 mg; 40 mg <b>Oral liquid:</b> 5mg/5ml	P, S, T	<b>POM</b>
	Adrenaline (Epinephrine)	<b>Injection:</b> 1 mg/mL [1 in 1000], 0.5 mg/mL [1 in 10000]  <b>Auto Injector:</b> 0.15mg, 0.30mg	P, S, T	<b>Restricted for Health Facilities</b>  <b>POM</b>
	Fexofenadine	<b>Tablet:</b> 120 mg, 180 mg <b>Syrup:</b> 30mg/5ml	P, S, T	<b>OTC</b>
	Pheniramine	<b>Tablet:</b> 25mg, <b>Syrup:</b> 15 mg/5ml <b>Injection:</b> 25mg/ml	P, S, T	<b>POM</b>
4	<b>ANTIDOTES AND OTHER SUBSTANCES USED IN POISONING</b>			
4.1	<b>Non specific</b>			
	Charcoal, Activated	<b>Powder:</b> 50 g cans or pack	P, S, T	<b>POM</b>
4.2	<b>Specific</b>			
	Acetylcysteine	<b>Injection:</b> 200 mg/ml in 10 mL – ampoule <b>Tablet:</b> 600 mg	P, S, T	<b>Restricted for Health Facilities</b> <b>POM</b>
	Atropine	<b>Injection:</b> 0.6 mg; 1 mg in 1 mL-ampoule	P, S, T	<b>Restricted for Health Facilities</b>
	Desferrioxamine (Deferoxamine)	<b>Injection:</b> 500 mcg/mL [mesylate] in ampoule	S, T	<b>POM</b>
	Flumazenil	<b>Injection:</b> 100mcg /mL	S, T	<b>Restricted for Health Facilities</b>
	Naloxone	<b>Injection:</b> 400 mcg [HCl] in 1 mL ampoule	P, S, T	<b>Restricted for Health Facilities</b>
	Sodium Nitrite	<b>Injection:</b> 30 mg/mL in 10 mL ampoule	S, T	<b>POM</b>
	Deferiprone	<b>Tablet:</b> 500 mg	S, T	<b>POM</b>
	Deferasirox	<b>Tablet:</b> 125 mg; 250 mg; 500	S, T	<b>POM</b>
	Dantrolene sodium	<b>Injection:</b> 20 mg	S, T	<b>Restricted for Health Facilities</b>
5	<b>MEDICINES FOR DISEASES OF THE NERVOUS SYSTEM</b>			
5.1	<b>Antiseizure medicines</b>			
	Carbamazepine	<b>Oral liquid:</b> 100 mg/5mL, Tablet scored 100 mg, 200 mg.	P, S, T	<b>POM</b>

	Diazepam	<b>Injection:</b> 5mg/mL in a 2 mL ampoule intravenous <b>Tablet:</b> 1mg, 2mg, 5mg, 10mg <b>Oral liquid:</b> 2mg/5mL	P, S, T	Controlled
	Lorazepam	<b>Tablet:</b> 1 mg; 2 mg <b>Injection:</b> 1 mg/ml, 2mg/ml	P, S, T	Controlled
	Magnesium sulphate	Injection: 500mg/mL in 10mL ampoule, 250 mg/mL in 5 mL ampoule	S, T	Restricted for Health Facilities
	Phenobarbital	<b>Oral liquid:</b> 20 mg/5mL <b>Tablet:</b> 30 mg; 60 mg <b>Injection:</b> 200 mg/mL	P, S, T	Controlled
	Phenytoin sodium	<b>Injection:</b> 50 mg/mL [sodium salt] in 5 mL vial <b>Oral liquid:</b> 125 mg/5mL and 30mg/5 mL <b>Tablet:</b> 25 mg, 50 mg, and 100 mg [sodium salt]	P, S, T	<b>POM</b>
	Valproic acid (Sodium Valproate)	<b>Oral liquid:</b> 200mg/5 mL <b>Tablet enteric coated:</b> 200 mg; 500 mg [sodium salt]  <b>Injection:</b> 100 mg/mL	P, S, T	<b>POM</b>
	Levetiracetam	<b>Tablet:</b> 500mg <b>Syrup:</b> 100mg/mL <b>Injection:</b> 5mg/ml, 10mg/ml in 100ml	S, T	<b>POM</b>
6	<b>ANTI-INFECTIVE MEDICINES</b>			
6.1	<b>Anthelmintics</b>			
6.1.1	<b>Intestinal anthelmintics</b>			
	Albendazole	<b>Oral liquid:</b> 200 mg/5mL <b>Tablet:</b> 200 mg; 400 mg	P, S, T	<b>OTC</b>
	Mebendazole	<b>Tablet:</b> 100 mg <b>Syrup:</b> 100 mg/5mL	P, S, T	<b>OTC</b>
	Ivermectin	<b>Tablet:</b> 3mg	P, S, T	<b>POM</b>
6.1.2	<b>Anti filariasis</b>			
	Diethylcarbamazine	<b>Tablet:</b> 50 mg; 100 mg	NP	<b>NP</b>
6.2	<b>Antibacterials</b>			
	<p>To assist the development of tools for antibiotic stewardship program at local, national or global level, and to reduce antimicrobial resistance, a new antibiotic classification has been made by the World Health Organization, whereby antibiotics are categorized into Access, Watch and Reserve [AWaRe] groups.</p> <p>The "<b>Access</b>" group of antibiotics, as defined by the World Health Organization (WHO) under the AWaRe classification, comprises medications effective against a broad spectrum of commonly encountered, susceptible pathogens. These antibiotics are associated with a lower risk of developing resistance compared to those in the "Watch" and "Reserve" categories. Consequently, they are recommended as first- or second-line empiric treatment options for various infectious syndromes, as reviewed by the WHO Expert Committee on the Selection and Use of Essential Medicines. To enhance their availability and promote appropriate use, selected Access group antibiotics are individually listed on the WHO Model List</p>			

	<p>of Essential Medicines. These essential antibiotics should be widely accessible, affordable, and of assured quality.</p> <p><b>The watch group includes antibiotic classes that have a higher potential for microbial resistance.</b> These antibiotics should become the priority target of the antibiotic stewardship program and monitoring. Selected Watch group antibiotic is recommended as the first or second choice of empirical treatment options for a limited number of specific infection syndromes.</p> <p><b>The reserve group includes antibiotics and antibiotic classes that should be reserved for the treatment of confirmed or suspected infections due to multidrug-resistant organisms.</b> Reserve group antibiotics should be treated as a last resort option. These antibiotics should be accessible, but their use should be tailored to particular patients and settings, when other alternatives have failed or are not suitable. These antibiotics could be protected and prioritized as key targets of national and international stewardship programs involving monitoring and utilization reporting, to preserve their effectiveness.</p> <p><b>Source:</b> World Health Organization Model List of Essential Medicines – 23rd List (2023)</p>			
6.2.1	<b>Access group antibiotics</b>			
	Amikacin <small>access group</small>	<b>Injection:</b> 250mg [as sulphate] in 2 mL – vial Powder for injection: 1mg/vial	P, S, T	POM
	Amoxicillin <small>access group</small>	Capsule: 250 mg; 500 mg (anhydrous) Powder for oral suspension: 125 mg (anhydrous)/5 mL	P, S, T	POM
	Amoxicillin + clavulanic acid <small>access group</small>	<b>Oral liquid:</b> 228mg/5ml 200mg+28mg/5ml <b>Oral drop:</b> 62.5 mg/mL <b>Powder for injection:</b> 600 mg, 1.2 g in a vial. <b>Tablet:</b> 625 mg; 375 mg	P, S, T	POM
	Ampicillin <small>access group</small>	<b>Tablet/capsule:</b> 500 mg <b>Powder for injection:</b> 500 mg; 1 g (as sodium salt) in a vial.	P, S, T	POM
	Benzathine benzylpenicillin <small>access group</small>	Powder for injection: 1.44 g benzylpenicillin (=2.4 million IU), in 5-ml vial; 1.2million IU	P, S, T	Restricted for Health Facilities
	Procaine benzylpenicillin <small>access group</small>	<b>Injection:</b> 1.2 million IU	S, T	Restricted for Health Facilities
	Phenoxymethylpenicillin or penicillin V <small>access group</small>	<b>Tablet:</b> 250 mg; 500 mg <b>Syrup:</b> 125 mg/5mL	P, S, T	POM
	Chloramphenicol <small>access group</small>	<b>Capsule:</b> 250 mg, Oral suspension: 125 mg/5mL [palmitate] Powder for <b>Injection:</b> 1 gram sodium succinate in a vial	P, S, T	POM
	Doxycycline <small>access group</small>	Capsule or Tablet:100 mg (hydrochloride)	P, S, T	POM
	Flucloxacillin <small>access group</small>	<b>Tablet/Capsule:</b> 250mg; 500mg	P, S, T	POM



	Gentamycin <small>access group</small>	Injection: 10mg; 40 mg (as sulfate)/ml in 2-ml vial	P, S, T	<b>POM</b>
	Metronidazole <small>access group</small>	<b>Tablet:</b> 200 mg, 400 mg <b>Oral suspension:</b> 100 mg (as benzoate)/5 ml <b>Injection:</b> 500 mg <b>Gel:</b> 0.75 %	P, S, T	<b>POM</b>
	Sulfamethoxazole + Trimethoprim <small>access group</small>	<b>Tablet:</b> 400 mg + 80 mg <b>Oral suspension:</b> 200 mg + 40 mg/5 mL	P, S, T	<b>POM</b>
	Nitrofurantoin <small>access group</small>	<b>Tablet/Capsule:</b> 100mg	P, S, T	<b>POM</b>
	Cefazolin <small>access group</small>	<b>Injection:</b> 500mg; 1gm	S, T	<b>POM</b>
6.2.2	<b>Watch group antibiotics</b>			
	Azithromycin <small>watch group</small>	<b>Tablet:</b> 250 mg; 500mg <b>Oral liquid:</b> 100g/5ml	S, T	<b>POM</b>
	Cefadroxil <small>watch group</small>	<b>Tablet:</b> 250mg; 500mg <b>Syrup:</b> 125mg/5ml, 250mg/5ml	S, T	<b>POM</b>
	Cefixime <small>watch group</small>	<b>Tablet:</b> 100mg; 200mg; 400mg. <b>Syrup:</b> 50mg/5mL	S, T	<b>POM</b>
	Cefotaxime <small>watch group</small>	<b>Injection:</b> 250mg; 500 mg; 1g	S, T	<b>POM</b>
	Ceftazidime <small>watch group</small>	Powder for injection: 250mg (as pentahydrate) in vial	S, T	<b>POM</b>
	Ceftriaxone <small>watch group</small>	<b>Injection:</b> 250 mg; 1 g	S, T	<b>POM</b>
	Cefuroxime <small>watch group</small>	<b>Tablets:</b> 125 mg; 250mg (as cefuroxime axetile) <b>Injections:</b> 250 mg; 500 mg, 1000 mg <b>Oral Suspension:</b> 125 mg/5 ml	S, T	<b>POM</b>
	Erythromycin <small>watch group</small>	Capsule or <b>Tablet:</b> 250mg (as stearate or ethyl succinate); Powder for oral suspension: 125 mg (as stearate or ethyl succinate)/5ml; Powder for injection: 500 mg (as lactobionate) in a vial	P, S, T	<b>POM</b>
	Ciprofloxacin <small>watch group</small>	<b>Tablet:</b> 250 mg; 500mg (as hydrochloride), <b>Suspension:</b> 250mg/5ml <b>Injection:</b> 200mg/100ml (2mg/ml), <b>Solution</b> eye/ear drop: 0.3 %, Eye/ear ointment: 0.3%	S, T	<b>POM</b>
	Piperacillin + tazobactam <small>watch group</small>	<b>Injection:</b> 2.25g, 4.5g	S, T	Restricted for Health Facilities
	Meropenem <small>watch group</small>	Powder for injection: 500 mg (as trihydrate); 1 g (as trihydrate) in a vial	T	<b>POM</b>
	Vancomycin <small>watch group</small>	Powder for injection: 250mg; 500 mg in a vial	T	Restricted for Health Facilities

6.2.3	<b>Reserve group antibiotics</b>			
	Colistin <small>Reserve group</small>	Powder <b>Injection:</b> 1 million units IU in a vial	T	Restricted for Health Facilities
	Linezolid <small>Reserve group</small>	Injection: 2 mg/ml, Tablets: 400mg, 600 mg, Powder for oral liquid 100 mg/5 ml	T	Restricted for Health Facilities
6.3	<b>Anti-leprosy medicines</b> Medicines used in the treatment of leprosy should be used in combination. Combination therapy is essential to prevent the emergence of resistance.			
	Clofazimine	<b>Capsule:</b> 50 mg; 100 mg	NP	Restricted and to be used for the National program only
	Dapsone	<b>Tablet:</b> 25 mg; 50 mg; 100 mg	NP	Restricted and to be used for the National program only
	Rifampicin	<b>Capsule:</b> 150 mg; 300 mg	NP	Restricted and to be used for the National program only
6.4	<b>Anti-tuberculosis medicines</b>			
6.4.1	<b>First-line drugs</b>			
	Ethambutol	<b>Tablet:</b> 100 mg; 400 mg; 600 mg	NP	Restricted and to be used for the National program only
	Isoniazid	<b>Tablet:</b> 100 mg; 300 mg; tablet [scored]50 mg	NP	Restricted and to be used for the National program only
	Pyrazinamide	<b>Tablet:</b> 400 mg; 500 mg; 750 mg; 1000 mg	NP	Restricted and to be used for the National program only
	Rifampicin	<b>Tablet/Capsule:</b> 150 mg; 300 mg <b>Syrup:</b> 100 mg/5mL; 200 mg/5mL	NP	Restricted and to be used for the National program only
	Rifampicin + Isoniazid	<b>Tablet /Capsule:</b> 150mg+ 75 mg; 300 mg + 150 mg; 60 mg +30 mg; 75 mg + 50 mg; 60 mg + 60 mg	NP	Restricted and to be used for the National program only
	Rifampicin + Isoniazid + Ethambutol	<b>Tablet/Capsule:</b> 150mg+ 75mg + 275mg	NP	Restricted and to be used for the National program only
	Rifampicin + Isoniazid + Pyrazinamide + Ethambutol	<b>Tablet/Capsule:</b> 150mg + 75mg + 400mg + 275mg	NP	Restricted and to be used for the National program only
	Streptomycin	<b>Powder for Injection:</b> 1 g in a vial [sulphate]	NP	Restricted for Health Facilities
	Pyridoxine	<b>Tablet:</b> 50mg; 40mg	NP	POM
6.4.2	<b>Second-line drugs for the treatment of multidrug-resistant tuberculosis [MDR TB] should be used, adhering to the WHO Standards for TB control</b>			
	Amikacin <small>access group antibiotic</small>	Powder for <b>Injection:</b> 1 g in a vial	NP	Restricted for Health Facilities

	Cycloserine	Tablet or <b>Capsule:</b> 250 mg	NP	<b>Restricted and to be used for the National program only</b>
	Ethionamide	<b>Tablet:</b> 125 mg; 250 mg	NP	<b>Restricted and to be used for the National program only</b>
	Kanamycin	Powder for <b>Injection:</b> 1 g in a vial	NP	Restricted for Health Facilities
	Ofloxacin	<b>Tablet:</b> 100 mg; 200 mg; 400 mg Eye solution: 0.3%	NP	Restricted for Health Facilities
6.5	<b>Antifungal medicines</b>			
	Fluconazole	Tablet or <b>Capsule:</b> 50 mg; 100 mg; 150 mg Oral suspension: 50 mg/5mL <b>Injection:</b> 2mg/mL in a vial	P, S, T	<b>POM</b> Restricted for Health Facilities
	Griseofulvin	Tablet or <b>Capsule:</b> 125 mg; 250 mg	P, S, T	<b>POM</b>
	Nystatin	<b>Lozenges:</b> 100 000 IU, <b>Pessary:</b> 100 000 IU <b>Tablet:</b> 100 000 IU; 500 000 IU <b>Syrup:</b> 100000 IU/ml	S, T	<b>POM</b>
	Itraconazole	<b>Tablet:</b> 100 mg; 200 mg	S, T	<b>POM</b>
	Amphotericin B	<b>Injection:</b> 50mg/vial (Lypholized), (as sodium deoxycholate or liposomal complex).	T	<b>POM</b>
	Clotrimazole	<b>Vaginal tablets:</b> 100 mg; 200 mg <b>Gel:</b> 1 %; 10 % <b>Cream:</b> 1%	P, S, T	<b>POM</b>
6.6	<b>Antiviral medicines</b>			
6.6.1	<b>Anti-herpes medicines</b>			
	Acyclovir	<b>Cream:</b> 3 %, 5 % <b>Injection:</b> 250mg [sodium salt] in a vial <b>Tablet:</b> 200 mg; 400 mg; 800 mg <b>Oral Liquid:</b> 200 mg/5mL	S, T	<b>POM</b>
6.6.2	<b>Antiretrovirals</b>			
6.6.2.1	<b>Nucleoside/nucleotide reverse transcriptase inhibitor.</b>			
	Abacavir [ABC]	<b>Oral liquid:</b> 100 mg/5mL [as sulphate] <b>Tablet:</b> 300 mg [as sulphate]	NP	<b>Restricted and to be used for the National program only</b>
	Lamivudine [3TC]	<b>Oral liquid:</b> 50 mg/5 mL <b>Tablet:</b> 150 mg	NP	<b>Restricted and to be used for the National program only</b>
	Tenofovir disoproxil fumarate [TDF]	<b>Tablet:</b> 300 mg [Tenofovir disopropyl fumarate equivalent to 245 mg tenofovir disoproxil]	NP	<b>Restricted and to be used for the National program only</b>

	Zidovudine [ZDV or AZT]	<b>Capsule:</b> 100 mg; 250 mg <b>Oral liquid:</b> 50 mg/5mL Solution for IV infusion: 10mg/mL in 20 mL vial <b>Tablet:</b> 100 mg; 300 m	NP	Restricted and to be used for the National program only
	Entecavir	<b>Tablet:</b> 0.5 mg; 1 mg	NP	Restricted and to be used for the National program only
	Tenofovir + Emtricitabine	<b>Tablet:</b> 300 mg + 200 mg	NP	Restricted and to be used for the National program only
6.6.2.2	<b>Non-nucleoside reverse transcriptase inhibitors.</b>			
	Efavirenz [EFV or EFZ]	<b>Capsule:</b> 50 mg; 100 mg; 200 mg <b>Oral liquid:</b> 150 mg/5mL <b>Tablet:</b> 600 mg	NP	Restricted and to be used for the National program only
	Nevirapine [NVP]	<b>Oral liquid:</b> 50 mg/5mL <b>Tablet:</b> 200 mg	NP	Restricted and to be used for the National program only
6.6.2.3	<b>Protease inhibitors</b>			
	Lopinavir + Ritonavir [LPV/R]	<b>Capsule:</b> 133.3 mg + 33.3 mg <b>Oral liquid:</b> 400 mg + 100 mg/5 mL	NP	Restricted and to be used for the National program only
	Nelfinavir [NFV]	<b>Tablet:</b> 250mgas mesylate <b>Oral Powder:</b> 50 mg/g	NP	Restricted and to be used for the National program only
	Ritonavir	<b>Oral liquid:</b> 400 mg/5 mL Capsule or <b>Tablet:</b> 100 mg	NP	Restricted and to be used for the National program only
6.6.2.4	<b>Fixed-dose combination</b>			
	Efavirenz + Emtricitabine + Tenofovir	<b>Tablet:</b> 600 mg + 200 mg + 300 mg	NP	Restricted and to be used for the National program only
	Emtricitabine + Tenofovir	<b>Tablet:</b> 200 mg + 300 mg	NP	Restricted and to be used for the National program only
	Zidovudine + Lamivudine	<b>Tablet:</b> 300 mg + 150 mg	NP	Restricted and to be used for the National program only
	Zidovudine + Lamivudine + Nevirapine	<b>Tablet:</b> 300 mg + 150mg+ 200 mg	NP	Restricted and to be used for the National program only
	Emtricitabine + Rilpivirine + Tenofovir	<b>Tablet:</b> 600 mg + 300 mg + 200 mg; 200 mg+ 300 mg + 600 mg	NP	Restricted and to be used for the National program only
6.6.2.5	<b>Medicines for Hepatitis [B and C]</b>			
	Sofosbuvir [ for hepatitis C]	<b>Tablet:</b> 400 mg	NP	Restricted and to be used for the National program only

	Lepidasvir + Sofosbuvir [for hepatitis C]	<b>Tablet:</b> 90 mg + 400 mg	NP	Restricted and to be used for the National program only
	Dataclasvir	<b>Tablet:</b> 90 mg	NP	Restricted and to be used for the National program only
	Ribavarin [for hepatitis C]	<b>Capsule:</b> 200 mg	NP	Restricted and to be used for the National program only
	Tenofovir [Hepatitis B]	<b>Tablet:</b> 300 mg	NP	Restricted and to be used for the National program only
	Entecavir [hepatitis B]	<b>Tablet:</b> 0.5 mg	NP	Restricted and to be used for the National program only
6.6.2.6	<b>Other antivirals</b>			
	Oseltamivir	<b>Capsule:</b> 30 mg; 45 mg; 75 mg <b>Oral liquid:</b> 12 mg/mL	P, S, T	POM
6.7	<b>Antimalarial medicines</b>			
	Mefloquine	<b>Tablet:</b> 250 mg	NP	Restricted and to be used for the National program only
	Quinine	<b>Tablet:</b> 100 mg; 300 mg <b>Injection:</b> 300 mg/mL in 2 mL ampoule	NP	Restricted and to be used for the National program only
	Chloroquine	<b>Tablet:</b> 150 mg	NP	Restricted and to be used for the National program only
	Sulphadoxine + pyrimethamine	<b>Tablet:</b> 500 mg + 25 mg	NP	POM
	Primaquine	<b>Tablet:</b> 7.5 mg; 15 mg	NP	Restricted and to be used for the National program only
	Artesunate	<b>Tablet:</b> 150 mg <b>Rectal suppository:</b> 50 mg; 100 mg; 200 mg <b>Injection:</b> 150mg in vials	NP	Restricted and to be used for the National program only
	Artemether	<b>Tablet:</b> 80 mg <b>Injection:</b> 80 mg/mL in 1 mL ampoule	NP	Restricted and to be used for the National program only
	Proguanil	<b>Tablet:</b> 100 mg	NP	Restricted and to be used for the National program only
	Doxycycline <sup>access group</sup> antibiotic	<b>Capsule/Tablet:</b> 100 mg	P, S, T	POM
	Artemether + lumefantrine	<b>Tablet:</b> 20 mg + 120 mg	NP	Restricted and to be used for the National program only

	Artesunate + lumefantrine	<b>Tablet:</b> 20 mg + 120 mg	NP	<b>Restricted and to be used for the National program only</b>
	Artesunate + mefloquine	<b>Tablet:</b> 25 mg + 55 mg, 100 mg + 220 mg	NP	<b>Restricted and to be used for the National program only</b>
	Mefloquine	<b>Tablet:</b> 250mg	NP	<b>Restricted and to be used for the National program only</b>
6.8	<b>Anti-pneumocystis and anti-toxoplasmosis</b>			
	Sulphadiazine	<b>Tablet:</b> 500 mg	T	<b>POM</b>
	Pyrimethamine	Tablet: 25 mg	S, T	<b>POM</b>
	Spiramycin	<b>Tablet:</b> 1.5 million IU; 3 million IU	P, S, T	<b>POM</b>
	Folinic acid/leucovorin	<b>Tablet:</b> 5 mg; 10mg <b>Injection:</b> 10mg/ml, 50mg/ml	S, T	<b>POM</b>
7	<b>ANTIMIGRAINE MEDICINES</b>			
7.1	<b>For the treatment of an acute attack</b>			
	Acetyl salicylic acid	<b>Tablet:</b> 75 mg; 150 mg; 300 mg	P, S, T	POM
	Paracetamol	<b>Tablet:</b> 500mg <b>Oral liquid:</b> 120 mg/5 mL; 250 mg/5 mL <b>Oral Drops:</b> 100 mg/ml <b>Suppository:</b> 125 mg; 250 mg <b>Injection:</b> 100mg/ml, 150mg/ml	P, S, T	OTC       <b>POM</b>
	Sumatriptan	<b>Tablet:</b> 25 mg; 50 mg	T	<b>POM</b>
7.2	<b>For prophylaxis</b>			
	Propranolol	<b>Tablet:</b> 5mg; 10mg; 40 mg	P, S, T	POM
	Flunarizine	<b>Tablet:</b> 5 mg; 10mg	S, T	POM
	Topiramate	<b>Tablet:</b> 25 mg; 50 mg	S, T	POM
8	<b>ANTINEOPLASTICS, IMMUNOSUPPRESSIVES AND MEDICINES USED IN PALLIATIVE CARE</b>			
8.1	<b>Immunosuppressive medicines</b>			
	Azathioprine	Powder for <b>Injection:</b> 100 mg [sodium salt] in vial <b>Tablet:</b> 50 mg	S, T	<b>POM</b>
	Cyclosporin	<b>Capsule:</b> 25 mg Concentrate for <b>Injection:</b> 50 mg/mL in 1 mL ampoule.	S, T	<b>POM</b>
	Tacrolimus	<b>Tablet:</b> 1 mg; 2 mg <b>Ointment:</b> 0.03 %; 0.1 %	P, S, T	<b>POM</b>

	Mycophenolate mofetil	<b>Tablet:</b> 500 mg; 360 mg	P, S, T	<b>POM</b>
	Ticagrelor	<b>Tablet:</b> 90mg, 180mg	S, T	<b>POM</b>
	Calcipotriol	<b>Ointment:</b> 0.005%	P, S, T	<b>POM</b>
8.2	<b>Anti-neoplastic medicines</b>			
	Cyclophosphamide	<b>Powder for Injection:</b> 500mg, 1000mg <b>Injection:</b> 500mg/2.5mL  <b>Tablet:</b> 25 mg; 50 mg	S, T	Restricted for Health Facilities  <b>POM</b>
	Methotrexate	<b>Powder for Injection:</b> 50mg <b>Injection:</b> 50mg/2ml, 250mg/10ml <b>Tablet:</b> 2.5 mg; 5 mg	S, T	Restricted for Health Facilities <b>POM</b>
	Imatinib	<b>Tablet:</b> 100 mg; 400 mg	T	<b>POM</b>
	Hydroxyurea	<b>Tablet:</b> 200 mg; 300 mg	T	<b>POM</b>
	Rituximab	Injection 10mg/mL	T	Restricted for Health Facilities
	Abiraterone	Tablet: 500 mg	T	POM
	Adriamycin	Injection: 50 mg/25 ml	T	Restricted for Health Facilities
	Bicalutamide	Tablet: 50mg and 150 mg	T	POM
	Bleomycin	<b>Powder for Injection:</b> 15000 IU (as sulfate) in vial	T	Restricted for Health Facilities
	Bortezomib	<b>Powder for Injection:</b> 3.5mg	T	Restricted for Health Facilities
	Capecitabine	<b>Tablet:</b> 500mg	T	POM
	Carboplatin	<b>Tablet:</b> 150mg, 500mg	T	POM
	Cisplatin	<b>Injection:</b> 10mg/10mL, 20mg/20mL, 50mg/50mL	T	Restricted for Health Facilities
	Dacarbazine	<b>Powder for Injection:</b> 100mg, 200mg in a vial	T	Restricted for Health Facilities
	Etoposide	<b>Capsule:</b> 50mg, 100mg <b>Injection:</b> 20mg/mL in 5 mL ampoule <b>Powder for Injection:</b> 100mg (as phosphate) in vial	T	POM Restricted for Health Facilities
	Letrozole	Tablet: 2.5mg	T	POM
	Fluorouracil	Injection: 50mg/mL in a vial	T	Restricted for Health Facilities
	Folinic acid/leucovorin	<b>Tablet:</b> 5 mg; 10mg  <b>Injection:</b> 10mg/ml, 50mg/ml	S, T	<b>POM</b>  Restricted for Health Facilities
	Gemcitabine	Powder for Injection: 200mg, 1g in a vial	T	Restricted for Health Facilities

	Trastuzumab	Powder for Injection: 60mg, 150mg, 440mg in a vial	T	Restricted for Health Facilities
	Ifosfamide	Powder for Injection: 500mg, 1g in a vial	T	Restricted for Health Facilities
	Irinotecan	Injection: 40mg/2mL in 2mL vial, 100mg/5mL in 5mL vial, 500mg/25mL in 25mL vial.	T	Restricted for Health Facilities
	Lenvatinib	Capsule: 4mg, 8mg, 10mg	T	POM
	Octreotide	Depot: 10mg, 20mg	T	Restricted for Health Facilities
	Oxaliplatin	Injection: 50mg/10mL in 10mL vial, 100mg/20mL in 20mL vial	T	Restricted for Health Facilities
	Paclitaxel	Injection: 6mg/mL in a vial	T	Restricted for Health Facilities
	Temozolomide	Capsule: 5mg, 20mg, 100mg	T	POM
	Vinblastine	Injection: 1mg/ml (1ml)	T	Restricted for Health Facilities
	Vincristine	Injection: 1mg/mL (sulfate); 2mg/2mL (sulfate) in vial	T	Restricted for Health Facilities
	Cytarabine	Injection: 100mg/1ml, 500mg/5ml	T	Restricted for Health Facilities
	Bortezomib	Powder for Injection: 3.5mg in a vial	T	Restricted for Health Facilities
	Dasatinib	Tablet: 20mg, 50mg, 70mg, 80mg	T	POM
	Ibrutinib	Capsule: 140mg	T	POM
	Filgrastim	Injection: 120 mcg/0.2mL, 300mcg/0.5mL, 480mcg/0.8mL in pre-filled syringe Injection: 300mcg/mL in 1mL vial; 480mcg/1.6 mL in 1.6ml vial	T	Restricted for Health Facilities
8.3	<b>Hormones and antihormones</b>			
	Dexamethasone	<b>Injection:</b> 4 mg dexamethasone phosphate [as disodium salt] in 1 ml ampoule	P, S, T	<b>POM</b>
	Hydrocortisone	<b>Powder for Injection:</b> 100 mg [sodium succinate] <b>Tablet:</b> 5mg, 10mg	P, S, T	<b>POM</b>
	Prednisolone	<b>Tablet:</b> 5 mg; 20 mg	P, S, T	<b>POM</b>
	Tamoxifen	<b>Tablet:</b> 10mg; 20 mg [as citrate]	S, T	<b>POM</b>
	Betamethasone	<b>Ointment/Cream:</b> 0.1 %; 0.05% [dipropionate] <b>Injection:</b> 6 mg/mL Tablet: 0.5mg	P, S, T	<b>POM</b>
	Fludrocortisone	<b>Tablet:</b> 0.1 mg	S, T	<b>POM</b>



	Cabergoline	<b>Tablet: 0.25mg</b>	T	POM
8.4	<b>Medicines used in palliative care</b>			
8.4.1	<b>Analgesics</b>			
	Ibuprofen	<b>Injection:</b> 5mg/ml, <b>Tablet:</b> 200 mg, 400 mg, <b>Oral liquid:</b> 100mg/5ml	P, S, T	OTC
	Morphine	<b>Oral liquid:</b> 10mg [HCl or sulphate]/5 mL <b>Tablet:</b> 10mg; 30mg modified release [sulphate]	S, T	Controlled
	Paracetamol	<b>Tablet:</b> 500mg <b>Oral liquid:</b> 120 mg/5 mL; 250 mg/5 mL <b>Oral Drops:</b> 100 mg/ml <b>Suppository:</b> 125 mg; 250 mg <b>Injection:</b> 100mg/ml, 150mg/ml	P, S, T	OTC  POM
8.4.2	<b>Antiemetics</b>			
	Ondansetron	<b>Injection:</b> 2mg/mL, 4mg/ml in 2 mL ampoule <b>Tablet:</b> 4 mg; 8 mg <b>Syrup:</b> 2 mg/5mL, 4mg/5ml	S, T	POM
	Metoclopramide	<b>Injection:</b> 5 mg (hydrochloride)/ml in 2- ml ampoule <b>Tablet:</b> 10mg (hydrochloride) Syrup: 5mg/5ml	P, S, T	POM
8.4.3	<b>Antispasmodics</b>			
	Hyoscine butyl bromide	<b>Injection:</b> 20 mg/mL <b>Tablet:</b> 10mg	P, S, T	POM
	Simethicone	<b>Tablet:</b> 80mg, 140mg <b>Drop:</b> 20mg/ml <b>Syrup:</b> 2 % emulsion/120ml	P, S, T	OTC
8.4.4	<b>Psychotherapeutic medicines</b>			
	Amitriptyline	<b>Tablet:</b> 10mg; 25 mg [HCl]	P, S, T	POM
	Midazolam	<b>Injection:</b> 1 mg/mL, 5 mg/mL in 2 mL ampoule <b>Tablet:</b> 7.5.mg Syrup: 2 mg/mL	P, S, T	CONTROLLED (NARCORTIC)
	Diazepam	<b>Injection:</b> 5 mg/mL <b>Oral liquid:</b> 2 mg/5mL <b>Tablet:</b> 5 mg; 10mg Rectal solution: 2.5.mg; 5 mg; 10mg	P, S, T	CONTROLLED (NARCORTIC)
9	<b>Anti parkinsonism medicines</b>			
	Levodopa + Carbidopa	<b>Tablet:</b> 100 mg + 10mg	S, T	POM
	Trihexyphenidyl HCl	<b>Tablet:</b> 2 mg <b>Injection:</b> 5mg (lactate) in mL ampoule	P, S, T	Restricted for Health Facilities
	Amantadine	<b>Tablet:</b> 100mg	P, S, T	POM

10	<b>MEDICINES AFFECTING BLOOD</b>			
10.1	<b>Anti-anaemia medicines</b>			
	Ferrous salt	<b>Oral solution:</b> equivalent to 25 mg elemental iron [as sulphate]/mL <b>Tablet:</b> equivalent to 60 mg iron	P, S, T	<b>POM</b>
	Ferrous Salt + folic acid	<b>Tablet:</b> equivalent to 60 mg iron + 400 mcg	P, S, T	<b>POM</b>
	Folic acid	<b>Tablet:</b> 1 mg; 5 mg, <b>Oral Liquid:</b> 2.5mg/5ml, 5 mg/ 5 ml	P, S, T	<b>POM</b>
	Iron (Parenteral)	<b>Injection:</b> 50mgiron/mL (Dextran/ Sucrose)	T	Restricted for Health Facilities
	Erythropoietin	<b>Injection:</b> 2000 IU/0,5 mL	T	<b>POM</b>
10.2	<b>Medicines affecting coagulation</b>			
	Heparin sodium	<b>Injection:</b> 1000 IU/mL; 2000 IU/mL in 2 mL ampoule	P, S, T	<b>POM</b>
	Enoxaparin	<b>Injection:</b> 40 mg [equivalent to 4000 IU]; 60mg [equivalent to 6000 IU]	S, T	<b>POM</b>
	Phytomenadione [vitamin K1]	<b>Injection:</b> 10mg/mL in 5 mL ampoule	P, S, T	<b>POM</b>
	Protamine Sulphate	<b>Injection:</b> 10mg/mL in 5 mL ampoule	S, T	<b>POM</b>
	Warfarin	<b>Tablet:</b> 1 mg; 2 mg, 3mg, 4mg, and 5 mg (sodium salt)	S, T	<b>POM</b>
	Tranexamic acid	<b>Tablet:</b> 100 mg; 500 mg <b>Injection:</b> 100 mg/mL in 10 mL – ampoule	T	<b>POM</b>
	Rivaroxaben	<b>Tablet:</b> 20mg	T	POM
11	<b>BLOOD PRODUCTS AND PLASMA SUBSTITUTES</b> <b>All blood products must meet WHO requirements</b>			
11.1	<b>Plasma substitutes</b>			
	Dextran	<b>Injectable solution:</b> Dextran 40	P, S, T	Restricted for Health Facilities
11.2	<b>Plasma fractions for specific use</b>			
	Human normal immunoglobulin	Intramuscular administration: 16 % protein solution Intravenous administration: 5 %; 10 % solution	S, T	Restricted for Health Facilities
	Fresh frozen plasma [FPP]	Injection	S, T	Restricted for Health Facilities
	Factor VIII concentrate	<b>Injection:</b> 500 IU/mL	S, T	Restricted for Health Facilities *Hemophilia
	Factor IX concentrate	<b>Injection:</b> 500 IU/mL	S, T	Restricted for Health Facilities *Hemophilia

	Albumin	<b>Injection:</b> 5 %; 10 %	S, T	Restricted for Health Facilities
11.3	<b>Blood products</b>			
	Blood	Whole blood and packed cells	P, S, T	Restricted for Health Facilities
	Platelet concentrate		S, T	
12	<b>CARDIOVASCULAR MEDICINES</b>			
12.1	<b>Antianginal medicines</b>			
	Glyceryl trinitrate	Tablet sublingual: 500 microgram Injection: 5 mg/ml ,	P, S, T	<b>POM</b>
	Isosorbide dinitrate	Tablet sublingual: 5 mg; 10mg	P, S, T	<b>POM</b>
	Isosorbide mononitrate	<b>Tablet:</b> 10mg, 20mg		
	Metoprolol	<b>Tablet:</b> 25 mg; 50 Injection :5mg	P, S, T	<b>POM</b>
	Verapamil	<b>Injection:</b> 2.5mg [HCl]/mL in 2 mL ampoule <b>Tablet:</b> 40 mg; 80 mg [HCl]	P, S, T	<b>POM</b>
	Sildenafil	<b>Tablet:</b> 20 mg Syrup: 10mg	T	<b>POM</b>
	Nitro-glycerine	Ointment 0.2 %, Injection: 25mg/5ml	S, T	<b>POM</b>
	Diltiazem	Injection: 25 mg/5mL	S, T	<b>POM</b>
12.2	<b>Antiarrhythmic medicines</b>			
	Amiodarone	<b>Tablet:</b> 100 mg; 200 mg Injection: 25mg/ml in 3ml	P, S, T	<b>POM</b>
	Digoxin	<b>Injection:</b> 250 micrograms/mL in 2mL ampoule  Oral solution: 50 microgram/mL <b>Tablet:</b> 62.5 microgram; 250 microgram	S, T	Restricted for Health Facilities  <b>POM</b>
	Isoprenaline [isopropyl adrenaline]	<b>Injection:</b> 2 mg [HCl]/mL in an ampoule	S, T	Restricted for Health Facilities
	Lidocaine	<b>Injection:</b> 2 mg [HCl]/mL in 5 mL ampoule	S, T	<b>POM</b>
	Verapamil	<b>Injection:</b> 2.5mg [HCl]/mL in 2 mL ampoule <b>Tablet:</b> 40 mg; 80 mg	S, T	<b>POM</b>
12.3	<b>Antihypertensive medicines</b>			
	Amlodipine	<b>Tablet:</b> 2.5 mg; 5 mg	P, S, T	<b>POM</b>
	Labetalol	<b>Tablet:</b> 100 mg; 200mg; 300 mg  <b>Injection:</b> 5 mg/mL	S, T	<b>POM</b>  Restricted for Health Facilities

	Enalapril	<b>Tablet:</b> 2.5 mg; 5 mg <b>Injection:</b> 1.25/mL	P, S, T	<b>POM</b>
	Hydralazine	<b>Injection:</b> 20 mg/mL [HCl] in ampoule	S, T	Restricted for Health Facilities
	Hydrochlorothiazide	<b>Tablet:</b> 25 mg; 12.5 mg	P, S, T	<b>POM</b>
	Losartan [potassium]	<b>Tablet:</b> 25 mg; 50 mg	P, S, T	<b>POM</b>
	Methyldopa	<b>Tablet:</b> 250 mg; 500 mg	S, T	<b>POM</b>
	Sodium nitroprusside	<b>Injection:</b> 50 mg/5mL in ampoule	T	<b>POM</b>
12.4	<b>Medicines used in heart failure</b>			
	Digoxin	<b>Tablet:</b> 62.5 microgram; 250 micrograms <b>Oral liquid:</b> 50 microgram/mL <b>Injection:</b> 250 microgram/mL in 2 mL ampoule	S, T	<b>POM</b> Restricted for Health Facilities
	Dopamine	<b>Injection:</b> 40 mg [HCl] in 5 ml vial	S, T	<b>POM</b>
	Carvedilol	<b>Tablet:</b> 1.25 mg; 6.25 mg, 25mg	S, T	<b>POM</b>
	Enalapril	<b>Tablet:</b> 2.5 mg; 5 mg	P, S, T	<b>POM</b>
	Furosemide	<b>Injection:</b> 10mg/mL in 2 mL ampoule <b>Syrup:</b> 20mg/5mL, 50mg/5mL <b>Tablet:</b> 20 mg; 40 mg	P, S, T	<b>POM</b>
	Hydrochlorothiazide	<b>Tablet:</b> 25 mg; 12.5 mg	P, S, T	<b>POM</b>
	Dobutamine	<b>Injection:</b> 250 mg/5mL, 250mg/20ml	P, S, T	<b>POM</b>
	Torsemide	<b>Tablet:</b> 10mg, 20mg	P, S, T	<b>POM</b>
	Eplerenone	<b>Tablet:</b> 25mg	P, S, T	<b>POM</b>
12.5	<b>Antithrombotic medicines</b>			
	Acetylsalicylic acid	<b>Tablet:</b> 75 mg; 100 mg	P, S, T	<b>POM</b>
	Clopidogrel	<b>Tablet:</b> 75 mg	P, S, T	<b>POM</b>
	Streptokinase	<b>Powder for injection:</b> 1.5 million IU in vial	P, S, T	Restricted for Health Facilities
	Alteplase	<b>Injection:</b> 20 mg; 30 mg; 50 mg	S, T	Restricted for Health Facilities
	Tenecteplase	<b>Injection:</b> 30mg, 40mg, 50mg	S, T	Restricted for Health Facilities
12.6	<b>Lipid lowering agent</b>			
	Atorvastatin	<b>Tablet:</b> 10mg; 20 mg; 30 mg	P, S, T	<b>POM</b>
	Rosuvastatin	<b>Tablet:</b> 10mg and 20mg	P, S, T	<b>POM</b>

13	<b>DERMATOLOGICAL MEDICINES</b>			
13.1	<b>Antifungal medicines</b>			
	Clotrimazole	<b>Cream:</b> 1 %; 2 % <b>Vaginal tablets:</b> 100 mg; 200 mg <b>Gel:</b> 1 %; 10 % <b>Solution:</b> 1%	P, S, T	<b>POM</b>
	Ketoconazole	<b>Cream:</b> 2%	P, S, T	<b>POM</b>
13.2	<b>Anti-infective medicines</b>			
	Silver Sulfadiazine	<b>Cream:</b> 1 %	P, S, T	<b>POM</b>
	Mupirocin	<b>Cream:</b> 2% (as calcium) <b>Ointment:</b> 2%	P, S, T	<b>POM</b>
	Fusidic acid	<b>Cream:</b> 2% <b>Ointment:</b> 2 %	P, S, T	<b>POM</b>
13.3	<b>Anti-inflammatory and anti-pruritic medicines</b>			
	Hydrocortisone	<b>Topical:</b> 0.5 %; 1 % [acetate]	P, S, T	<b>POM</b>
	Fluticasone	<b>Cream:</b> 0.05% <b>Ointment:</b> 0.005%	P, S, T	<b>POM</b>
	Clobetasol Propionate	<b>Cream:</b> 0.05% w/w <b>Ointment:</b> 0.05% w/w	P, S, T	<b>POM</b>
	Triamcinolone	<b>Oral Gel/Paste:</b> 0.1% <b>Injection:</b> 10mg, 40mg	P, S, T	<b>POM</b>
	Desonide	<b>Lotion:</b> 0.05%	P, S, T	<b>POM</b>
13.4	<b>Medicines affecting skin differentiation and proliferation</b>			
	Benzoyl peroxide	<b>Lotion and gel:</b> 2.5 %; 5 %	S, T	<b>POM</b>
	Podophyllum resin	<b>Solution:</b> 10 %; 25 %	S, T	<b>POM</b>
	Salicylic acid	<b>Solution:</b> 17% <b>Ointment:</b> 20 %	S, T	<b>POM</b>
	Tretinoin	<b>Cream</b> 0.025 %	P, S, T	<b>POM</b>
	Beclomethasone + Salicylic acid	<b>Ointment:</b> 0.1% + 3% w/w	P, S, T	<b>POM</b>
13.5	<b>Scabicides and pediculicides</b>			
	Permethrin	<b>Cream/lotion:</b> 5 % [for scabies]; 1 % [for lice]	S, T	<b>OTC</b>
14	<b>DIAGNOSTIC AGENTS</b>			
14.1	<b>Radio contrast media</b>			
	Amidotrizoate	<b>Injection:</b> 140 mg – 420 mg iodine [as sodium or meglumine salt]/mL in 20 mL ampoule	S, T	Restricted for Health Facilities

	Barium sulphate	Aqueous suspension/powder	T	<b>POM</b>
	Iohexol	<b>Injection:</b> 140 – 350 mg iodine/ML in 5 ML, 10 ML and 20 ML ampoule	S, T	Restricted for Health Facilities
	Gadolinium containing contrast for MRI	<b>Injection:</b> 287 mg/ML	S, T	Restricted for Health Facilities
	Diatrizoate Meglumine + Diatrizoate Sodium	Rectal and oral solution: 660 mg diatrizoate meglumine + 100 mg diatrizoate sodium/mL	S, T	Restricted for Health Facilities
14.2	<b>Others</b>			
	Methylene blue (methylthionium chloride)	Injection: 10mg/mL in 10mL ampoule	S, T	Restricted for Health Facilities
	Acetic acid	Solution: 2%, in alcohol	P, S, T	<b>POM</b>
15	<b>DESINFECTANTS AND ANTISPETICS</b>			
	<b>Antiseptics</b>			
	Chlorhexidine	<b>Solution:</b> 5 % (digluconate)	P, S, T	<b>OTC</b>
	Ethanol	<b>Solution:</b> 70% (denatured)	P, S, T	<b>POM</b>
16	<b>DIURETICS</b>			
	Furosemide	<b>Injection:</b> 10mg/mL in 2 mL ampoule <b>Tablet:</b> 40 mg	P, S, T	<b>POM</b>
	Hydrochlorothiazide	<b>Tablet:</b> 12.5 mg; 25 mg; 50 mg	P, S, T	<b>POM</b>
	Mannitol	Injectable solution: 10 %; 20 %	P, S, T	<b>POM</b>
	Spironolactone	<b>Tablet:</b> 25 mg; 50 mg	P, S, T	<b>POM</b>
17	<b>GASTROINTESTINAL MEDICINES</b>			
17.1	<b>Antacids and other antiulcer medicines</b>			
	Aluminium Magnesium based antacid	<b>Tablet:</b> 200 mg + 200 mg; 400 mg + 400 mg <b>Oral liquid:</b> 40mg /mL + 40 mg/mL	P, S, T	<b>POM</b>
	Ranitidine	<b>Injection:</b> 25 mg/mL in 2 mL ampoule <b>Oral liquid:</b> 75 mg/5mL <b>Tablet:</b> 150 mg	P, S, T	<b>POM</b>
	Pantoprazole	<b>Tablet:</b> 20 mg; 40 mg Oral liquid: 2mg/ml <b>Injection:</b> 40 mg in a vial	P, S, T	<b>POM</b>
	Lansoprazole	<b>Tablet:</b> 15mg <b>Oral liquid:</b> 3mg/ml	P, S, T	<b>POM</b>
	Simethicone	<b>Tablet:</b> 80mg, 140mg <b>Drop:</b> 20mg <b>Oral liquid:</b> 2 % emulsion	P, S, T	<b>POM</b>

	Ursodeoxycholic acid	<b>Tablet:</b> 150 mg; 300 mg	P, S, T	<b>POM</b>
<b>17.2</b>	<b>Anti-emetic medicines</b>			
	Domperidone	<b>Tablet:</b> 10mg <b>Oral liquid:</b> 5 mg/5mL	P, S, T	<b>POM</b>
	Ondansetron	<b>Injection:</b> 2mg/mL in 2 mL ampoule <b>Tablet:</b> 4 mg; 8 mg <b>Syrup:</b> 2 mg/5mL	P, S, T	<b>POM</b>
	Promethazine	<b>Injection:</b> 25mg [HCl]/mL <b>Oral liquid:</b> 5mg [HCl]/5ml <b>Tablet:</b> 10mg; 25mg [HCl]	P, S, T	<b>POM</b>
<b>17.3</b>	<b>Laxatives</b>			
	Bisacodyl	<b>Tablet:</b> 5mg <b>Suppository:</b> 10mg	P, S, T	<b>POM</b>
	Glycerin	Suppository: paediatric; adult	P, S, T	<b>OTC</b>
	Lactulose	Oral suspension	P, S, T	<b>OTC</b>
	Sodium phosphate monohydrate	Disposable enema		<b>POM</b>
<b>17.4</b>	<b>Medicines used for diarrhea</b>			
	Oral rehydration salt	<b>Powder for dilution</b>	P, S, T	<b>OTC</b>
	Elemental Zinc [sulphate]	<b>Tablet:</b> 10mg per unit dosage form <b>Oral liquid:</b> 10mg per unit dosage form	P, S, T	<b>POM</b>
<b>18</b>	<b>HORMONES and CONTRACEPTIVES</b>			
<b>18.1</b>	<b>Adrenocorticoid hormones</b>			
	Hydrocortisone	Powder for <b>Injection:</b> 100 mg/mL [sodium]	S, T	<b>POM</b>
	Dexamethasone	<b>Injection:</b> 4 mg [as disodium salt in 1 mL ampoule] <b>Tablet:</b> 0.5 mg	S, T	<b>POM</b>
	Methylprednisolone	<b>Injection:</b> 20 mg/mL; 40 mg/mL; 80 mg/mL <b>Tablet:</b> 2 mg; 4 mg	S, T	<b>POM</b>
	Prednisolone	<b>Oral liquid:</b> 5 mg/5mL <b>Tablet:</b> 5mg; 20mg	P, S, T	<b>POM</b>
	Betamethasone	<b>Ointment/Cream:</b> 0.1 %; 0.05% [dipropionate] <b>Injection:</b> 6 mg/mL Tablet: 0.5mg	P, S, T	<b>POM</b>
<b>18.2</b>	<b>Androgens</b>			

	Testosterone	<b>Capsule:</b> 40 mg <b>Injection:</b> 100 mg/mL; 200 mg/mL [enanthate] in 1 mL ampoule	S, T	Restricted for Health Facilities
	Danazol	<b>Tablet:</b> 100 mg; 200 mg	S, T	<b>POM</b>
<b>18.3</b>	<b>Contraceptives</b>			
<b>18.3.1</b>	<b>Hormonal contraceptives</b>			
	Levonorgestrel + Ethinylestradiol	<b>Tablet:</b> 0.15mg + 0.03mg	P, S, T	<b>POM</b>
	Norgestrel + Ethinylestradiol	<b>Tablet:</b> 0.5mg + 0.05mg	P, S, T	<b>POM</b>
<b>18.3.2</b>	<b>Intrauterine devices/implants</b>			
	Copper-containing device	IUCD [Copper T 380]	S, T	
	Levonorgestrel	IUD containing 52 mg <b>Implant:</b> 150mg	S, T	<b>POM</b>
	Etonogestrel-releasing implant	Implant containing 68 mg	S, T	Restricted for Health Facilities
<b>18.4</b>	<b>Estrogens</b>			
	Estradiol	<b>Tablet:</b> 10 mcg; 50 mcg, 2mg	P, S, T	<b>POM</b>
	Conjugated Estrogen	<b>Topical Cream:</b> 0.625mg/g, <b>Tablet:</b> 0.625mg	S, T	<b>POM</b>
	Levonorgestrel	<b>Tablet:</b> 0.75 mg, 1.50mg	P, S, T	<b>POM</b>
	Ethinylestradiol + cyproterone acetate	<b>Tablet:</b> 35 mcg + 2 mg [21 tablet packs]	S, T	<b>POM</b>
<b>18.5</b>	<b>Progestogens</b>			
	Dydrogesterone	<b>Tablet:</b> 10mg	P, S, T	<b>POM</b>
	Medroxyprogesterone	<b>Tablet:</b> 2.5 mg; 10mg	S, T	<b>POM</b>
	Medroxyprogesterone acetate	Depot <b>Injection:</b> 150 mg/mL in 1 mL vial [intramuscular] Tablet: 100mg	S, T	<b>POM</b>
	Micronized progesterone	<b>Tablet:</b> 25mg;75 mg; 100 mg; 200 mg	T	<b>POM</b>
	Lynesterol	<b>Tablet:</b> 0.5mg	S, T	Restricted and to be used for the National program only
<b>18.6</b>	<b>Ovulation inducer</b>			
	Clomiphene	<b>Tablet:</b> 25 mg; 50 mg; 100 mg	S, T	<b>POM</b>



	Human Chorionic Gonadotrophin	<b>Injection:</b> 5000 IU; 10 000 IU in vial	S, T	<b>POM</b>
<b>19.</b>	<b>MEDICINES FOR ENDOCRINE DISORDERS</b>			
<b>19.1</b>	<b>Insulin and other medicines for diabetes</b>			
	Insulin injection [soluble]	<b>Injection:</b> 100 IU/mL in 10 mL vial Pen: 100 IU/mL	P, S, T	<b>POM</b>
	Intermediate acting insulin [human]	Pen: 100 IU/mL	P, S, T	<b>POM</b>
	Insulin Glargine	Pen: 100 IU/mL	P, S, T	<b>POM</b>
	Insulin Detemir	Pen: 100 IU/mL	P, S, T	<b>POM</b>
	INSULIN aspart	Pen: 100 IU/mL	P, S, T	<b>POM</b>
	Sitagliptin	<b>Tablet:</b> 50 mg	S, T	<b>POM</b>
	Metformin	<b>Tablet:</b> 500 mg; 850 mg; 1000 mg SR [HCl]	P, S, T	<b>POM</b>
	Empagliflozin	<b>Tablet:</b> 10mg, 25mg	P, S, T	<b>POM</b>
	Glucagon	<b>Injection:</b> 1 mg/mL	S, T	<b>POM</b>
	Glimepiride	<b>Tablet:</b> 1 mg; 2 mg	P, S, T	<b>POM</b>
	Desmopressin	Nasal spray: 10 mcg/spray <b>Tablet:</b> 0.1 mg <b>Injection:</b> 4 mcg/mL	S, T	<b>POM</b>  Restricted for Health Facilities
<b>19.2</b>	<b>Thyroid hormones and antithyroid hormones</b>			
	Levothyroxine	<b>Tablet:</b> 25 micrograms; 50 micrograms; 75 microgram; 100 micrograms [sodium salt]	P, S, T	<b>POM</b>
	Propylthiouracil	<b>Tablet:</b> 50mg	S, T	<b>POM</b>
	Carbimazole	Tablet [film-coated]: 5 mg; 10mg	P, S, T	<b>POM</b>
<b>20</b>	<b>IMMUNOLOGICALS</b>			
<b>20.1</b>	<b>Diagnostic agents</b>			
	Tuberculin Purified Protein Derivative [PPD]	<b>Injection:</b> 5 IU; 10 IU	S, T	Restricted for Health Facilities
<b>20.2</b>	<b>Sera and immunoglobulins</b> All plasma fractions should comply with WHO Requirements for the Collection, Processing, and Quality Control of Blood, Blood Components, and Plasma Derivatives [ Revised 1992]. WHO Expert Committee on Biological Standardization, Forty-third report			
	Anti-D Immunoglobulin [human]	<b>Injection:</b> 300 micrograms in a single-dose vial	S, T	<b>POM</b>

	Anti-Tetanus immunoglobulin [human]	<b>Injection:</b> 250 IU; 500 IU S in vial	S, T	Restricted for Health Facilities
	Hepatitis B Immunoglobulin [HBIG]	<b>Injection:</b> 200 iU/mL	T	Restricted for Health Facilities
	IV immunoglobulin [IVIG]	Injection: 2.5 g/vial; 5 g/vial; 10 g/vial	T	Restricted for Health Facilities
	Varicella immunoglobulin [VZIG]	Injection	T	<b>Restricted and to be used for the National program only</b>
	Diphtheria antitoxin	<b>Injection:</b> 10 000 IU; 20 000 IU in vial	S, T	<b>Restricted and to be used for the National program only</b>
	Antivenom Immunoglobulin	Injection	S, T	Restricted for Health Facilities
<b>20.3</b>	<b>Vaccines</b> All vaccines should comply with the WHO Requirements for Biologicals			
<b>20.3.1</b>	<b>Universal immunization</b>			
	BCG vaccine		NP	Restricted for Health Facilities
	Hepatitis B vaccine		NP	<b>Restricted and to be used for the National program only</b>
	Measles vaccine		NP	<b>Restricted and to be used for the National program only</b>
	Poliomyelitis [oral] vaccine		NP	<b>Restricted and to be used for the National program only</b>
	Diphtheria, pertussis and tetanus vaccine		NP	<b>Restricted and to be used for the National program only</b>
	Diphtheria-Tetanus-Pertussis [whole cell] – Hepatitis B – Haemophilus influenza type b		NP	<b>Restricted and to be used for the National program only</b>
	Measles, mumps, rubella vaccines		NP	<b>Restricted and to be used for the National program only</b>
	Measles + rubella		NP	<b>Restricted and to be used for the National program only</b>

	Diphtheria + Tetanus		NP	Restricted and to be used for the National program only
	HiB vaccine		NP	POM
	Td vaccine		NP	Restricted for Health Facilities
	Corona virus Covid 19 vaccine		NP	Restricted and to be used for the National program only
<b>20.3.2</b>	<b>For specific group of individuals</b>			
	Influenza vaccine [inactivated]		NP	POM
	Meningococcal meningitis vaccine		NP	POM
	Yellow fever vaccine		NP	Restricted and to be used for the National program only
	Typhoid vaccine		NP	POM
	Cholera vaccine		NP	Restricted and to be used for the National program only
	Hepatitis A vaccine		NP	POM
	Varicella vaccine		NP	Restricted and to be used for the National program only
	Human papillomavirus [HPV] vaccine		NP	POM
	Pneumococcal polysaccharide vaccine		NP	POM
	Pneumococcal conjugated vaccine		NP	POM
	HiB vaccine		NP	POM
	Typhoid vaccine		NP	POM
	Rota Virus vaccine		NP	POM
<b>21</b>	<b>MUSCLE RELAXANTS AND CHOLINESTERASE INHIBITORS</b>			
	Atracurium	<b>Injection:</b> 10 mg/mL [besylate]	S, T	Restricted for Health Facilities
	Neostigmine	Injection: 500 mcg in 1 mL ampoule; 250 mcg in 1 mL ampoule [methyl sulphate] <b>Tablet:</b> 15 mg [bromide]	S, T	Restricted for Health Facilities  POM
	Suxamethonium	<b>Injection:</b> 50mg [Chloride]/mL in 2 mL ampoule	S, T	POM

	Pyridostigmine	<b>Injection:</b> 1 mg in 1 mL ampoule <b>Tablet:</b> 60 mg [bromide]	S, T	Restricted for Health Facilities  <b>POM</b>
	Rocuronium	<b>Injection:</b> 50 mg/5 mL	S, T	<b>Restricted for Hospital/Institutional use only</b>
	Baclofen	<b>Tablet:</b> 10mg <b>Oral liquid:</b> 10mg/5ml	S, T	<b>POM</b>
<b>22</b>	<b>OPHTHALMOLOGICAL PREPARATIONS</b>			
<b>22.1</b>	<b>Anti-infective agents</b>			
	Acyclovir	Ointment: 3 %	P, S, T	<b>POM</b>
	Ciprofloxacin <small>watch group antibiotic</small>	Eye drop/ointment: 0.3 %	P, S, T	<b>POM</b>
	Moxifloxacin	Eye drop – preservative-free	S, T	<b>POM</b>
	Tobramycin	Eye drop/ointment	P, S, T	<b>POM</b>  <b>POM</b>
	Fluconazole	Eye drop: 0.3 %	P, S, T	<b>POM</b>
<b>22.2</b>	<b>Anti-inflammatory agents</b>			
	Dexamethasone	Eye drop: 0.1%	P, S, T	<b>POM</b>
	Nepafenac	Eye drop: 0.1%	P, S, T	<b>POM</b>
	Tacrolimus	Eye ointment: 0.3 %	S, T	<b>POM</b>
<b>22.3</b>	<b>Local anaesthetics</b>			
	Tetracaine	Eye drop [solution]: 0.5 % [HCl]	S, T	Restricted for Health Facilities
	Lidocaine	Topical solution 4 %	S, T	Restricted for Health Facilities
	Proparacaine	Eye Drops: 0.5%	P, S, T	Restricted for Hospital/Institutional use only
<b>22.4</b>	<b>Miotics and antiglaucoma medicines</b>			
	Acetazolamide	<b>Tablet:</b> 250 mg	P, S, T	<b>POM</b>
	Latanoprost	Eye drop: 0.05 % (50mcg/ml)	S, T	<b>POM</b>
	Pilocarpine	Solution [eye drop]: 2 %; 4 % [HCl or nitrate]	S, T	<b>POM</b>
	Timolol	Solution/eye drop: 0.25 %; 0.5 % [maleate]	P, S, T	<b>POM</b>

<b>22.5</b>	<b>Mydriatics</b>			
	Phenylephrine	Solution/eye drop: 2.5 %	S, T	<b>POM</b>
	Cyclopentolate	Eye drop: 1 %	T	<b>POM</b>
	Tropicamide	Eye drop: 0.5 %; 0.1%	P, S, T	<b>POM</b>
	Atropine	Eye Drops: 1%	P, S, T	<b>POM</b>
<b>22.6</b>	<b>Medicines for allergic conditions</b>			
	Olopatadine	Eye solution: 0.1 %	P, S, T	<b>POM</b>
<b>22.7</b>	<b>Ocular lubricants</b>			
	Artificial tears		P, S, T	<b>OTC</b>
<b>22.8</b>	<b>Ophthalmic surgical aids</b>			
	Hydroxypropyl methyl cellulose	Solution: 2 %	T	<b>OTC</b>
	Trypan Blue	Solution 0.06%	T	Restricted for Health Facilities
	Lidocaine for intracameral use	Injection: 1%	T	<b>POM</b>
	Moxifloxacin for intracameral use	Injection: 150mcg/0.1 mL	T	<b>POM</b>
	Visco elastic	Pre-filled syringe: 2%	S, T	Restricted for Health Facilities
<b>22.9</b>	<b>Other ophthalmic preparation</b>			
	Sodium chloride	Solution: 5 %	T	<b>POM</b>
	Ranibizumab	Injection: 10mg/ml	T	Restricted for Health Facilities
	Fluorescein	Strips: 0.6mg Eye drops: 1% (sodium salt)	P, S, T	Restricted for Health Facilities
<b>23</b>	<b>MEDICINES ACTING ON THE GENITOURINARY TRACT</b>			
<b>23.1</b>	<b>Oxytoxics</b>			
	Oxytocin	Injection: 5 IU; 10 IU in 1 mL ampoule	P, S, T	Restricted for Health Facilities
	Mifepristone	<b>Tablet:</b> 200 mg	S, T	Restricted for Health Facilities
	Misoprostol	<b>Tablet:</b> 25 mcg; 50 mcg; 100mcg ; 200 mcg	S, T	Restricted for Health Facilities
	Ergometrine	<b>Injection:</b> 200 mcg [hydrogen maleate] in 1 mL ampoule	S, T	Restricted for Health Facilities
	PG F 2 alpha [Carboprost],	<b>Injection:</b> 250 mcg	S, T	Restricted for Health Facilities

<b>23.2</b>	<b>Antioxytoxics</b>			
	Nifedipine	Capsule/ <b>Tablet</b> : 10mg; retard 10mg; 20 mg	S, T	<b>POM</b>
<b>23.3</b>	<b>Medicines for benign prostatic hyperplasia</b>			
	Finasteride	<b>Tablet</b> : 1 mg; 5 mg	S, T	<b>POM</b>
	Prazosin	<b>Tablet</b> : 2mg	S, T	<b>POM</b>
	Tamsulosin	<b>Capsule</b> : 0.4mg	S, T	<b>POM</b>
<b>23.4</b>	<b>Urinary antispasmodics</b>			
	Oxybutynin	<b>Tablet</b> : 2.5mg, 5mg	S, T	<b>POM</b>
<b>23.5</b>	<b>Dialysis solution</b>			
	Hemodialysis concentrates for parenteral solution.		S, T	Restricted for Health Facilities
	Peritoneal dialysis solution		S, T	Restricted for Health Facilities
<b>24</b>	<b>PSYCHOTHERAPEUTIC MEDICINES</b>			
<b>24.1</b>	<b>Medicines used in psychotic disorders</b>			
	Chlorpromazine	<b>Oral liquid</b> : 25mg/5mL [HCL] <b>Tablet</b> : 100mg [HCl]	P, S, T	<b>POM</b>
	Fluphenazine	Injection/Depot: 25 mg decanoate or enanthate in 1 mL ampoule	P, S, T	<b>POM</b>
	Haloperidol	Injection: 5mg in 1mL ampoule, Depot: 50mg/mL <b>Tablet</b> : 0.25mg, 1.5mg, 2mg; 5mg Drops: 2mg/ml	P, S, T	<b>POM</b>
	Olanzapine	<b>Tablet</b> : 2.5.mg; 5 mg 10mg  Depot Injection: 210mg/vial, 300mg/vial, 405mg/vial	S, T	<b>Controlled</b>
	Risperidone	<b>Tablet</b> : 1mg, 2mg  <b>Oral liquid</b> : 1mg/ml  Depot Injection: 25mg/vial, 50mg/vial	S, T	<b>POM</b>
	Quetiapine	<b>Tablet</b> : 25mg; 50mg; 100mg; 300mg	S, T	<b>POM</b>
	Clozapine	<b>Tablet</b> : 25mg, 100mg,	S, T	<b>Controlled</b>
	Amisulpride	<b>Tablet</b> : 50mg, 100mg	S, T	<b>POM</b>
	Aripiprazole	<b>Tablet</b> : 5mg, 10mg, 20mg	S, T	<b>POM</b>
	Flupentixol	<b>Tablet</b> : 0.5mg	S, T	<b>POM</b>

<b>24.2</b>	<b>Medicines used in mood disorders</b>			
<b>24.2.1</b>	<b>Medicines used in depressive disorders</b>			
	Amitriptyline	<b>Tablet:</b> 10mg; 25 mg [HCl]	<b>P, S, T</b>	<b>POM</b>
	Fluoxetine	<b>Capsules:</b> 10mg, 20mg. Syrup: 20 mg/5mL	<b>P, S, T</b>	<b>POM</b>
	Imipramine	<b>Tablet:</b> 25 mg	<b>P, S, T</b>	<b>POM</b>
	Escitalopram	<b>Tablet:</b> 5 mg; 10mg	<b>P, S, T</b>	<b>POM</b>
	Mirtazapine	<b>Tablet:</b> 15 mg	<b>P, S, T</b>	<b>POM</b>
	Venlafaxine	<b>Tablet:</b> 25mg, 37.5mg, 75mg	<b>T</b>	<b>POM</b>
	Sertraline	<b>Tablet:</b> 50mg, 100mg	<b>S, T</b>	<b>POM</b>
	Bupropion	<b>Tablet:</b> 75 mg 150mg (ER)	<b>T</b>	<b>POM</b>
	Duloxetine	<b>Tablet:</b> 20mg	<b>P, S, T</b>	<b>POM</b>
<b>24.2.2</b>	<b>Medicines used in bipolar disorders</b>			
	Carbamazepine	<b>Tablet:</b> 100mg, 200mg	<b>P, S, T</b>	<b>POM</b>
	Sodium Valproate (Valproic acid)	<b>Tablet:</b> 200mg, 500mg (enteric coated)  <b>Oral liquid:</b> 200mg/5ml	<b>P, S, T</b>	<b>POM</b>
	Lithium	<b>Tablet:</b> 300mg, 450mg	<b>S, T</b>	<b>POM</b>
	Lamotrigine	<b>Tablet:</b> 25mg, 100mg	<b>S, T</b>	<b>POM</b>
<b>24.2.3</b>	<b>Medicines used in anxiety and sleep disorders</b>			
	Diazepam	<b>Tablet:</b> 1mg, 2mg, 5mg, 10mg <b>Oral liquid:</b> 2mg/5ml <b>Injection:</b> 5mg/5ml in 2ml	<b>P, S, T</b>	<b>Controlled</b>
	Chlordiazepoxide	<b>Tablet:</b> 10mg	<b>S, T</b>	<b>Controlled</b>
	Alprazolam	<b>Tablet:</b> 0.25mg, 0.5mg	<b>P, S, T</b>	<b>Controlled</b>
	Clonazepam	<b>Tablet:</b> 0.5mg; 2mg	<b>S, T</b>	<b>Controlled</b>
<b>24.2.4</b>	<b>Medicines used for obsessive-compulsive disorders</b>			
	Clomipramine	<b>Tablet/Capsule:</b> 10mg; 25 mg	<b>T</b>	<b>POM</b>
	Fluvoxamine	<b>Tablet:</b> 25mg, 50mg, 100mg	<b>T</b>	<b>POM</b>
<b>24.2.5</b>	<b>Medicines used in the substance dependence program</b>			
	Methadone [HCl]	Concentrate for <b>Oral liquid:</b> 5 mg/mL; 10mg/mL	<b>NP</b>	<b>Controlled</b>
	Nicotine Replacement Therapy [NRT]	Chewing gum: 2mg, 4mg [as polacrilex] Transdermal patch: 7mg, 14mg, 21mg	<b>P, S, T</b>	<b>POM</b>
	Clonidine	<b>Tablet:</b> 75mcg, 100mcg, 150 mcg	<b>S, T</b>	<b>POM</b>
	Naltrexone	<b>Tablet:</b> 50 mg	<b>T</b>	<b>Controlled</b>

	Buprenorphine	Tablet: 2 mg, 4 mg	<b>T</b>	<b>Controlled</b>
<b>24.6</b>	<b>Medicines used in child psychiatry</b>			
	Atomoxetine	<b>Tablet:</b> 10mg, 18mg, 25mg	<b>S, T</b>	<b>POM</b>
	Methylphenidate	<b>Capsule/ER Table:</b> 5mg, 10mg, 20mg, 25mg	<b>S, T</b>	Controlled
<b>24.7</b>	<b>Others</b>			
	Donepezil	<b>Tablet:</b> 5mg, 10mg	<b>T</b>	<b>POM</b>
	Memantine	<b>Tablet:</b> 5mg, 10mg	<b>S, T</b>	<b>POM</b>
<b>25</b>	<b>MEDICINES ACTING ON THE RESPIRATORY SYSTEM Anti-asthmatic and medicines for chronic obstructive pulmonary diseases</b>			
	Beclomethasone	Inhalation [aerosol] 50 microgram per dose [dipropionate]; 250 microgram per dose [dipropionate]	<b>P, S, T</b>	<b>POM</b>
	Epinephrine [adrenaline]	<b>Injection:</b> 1 mg [ as HCl or hydrogen tartrate] in 1 mL ampoule	<b>P, S, T</b>	Restricted for Health Facilities
	Ipratropium bromide	Inhalation [aerosol]: 20microgram/metered dose	<b>P, S, T</b>	<b>POM</b>
	Salbutamol	Inhalation [aerosol]: 100 micrograms per dose [as sulphate]  <b>Injection:</b> 0.5 mg/mL [as sulphate],  Respirator solution for nebulizer: 5mg,  <b>Tablet:</b> 2 mg; 4 mg	<b>P, S, T</b>	<b>POM</b>
	Theophylline	<b>Tablet/Capsule:</b> 100 mg; 200 mg; 300 mg <b>Syrup :</b> 80 mg/15 mL	<b>P, S, T</b>	<b>POM</b>
<b>26</b>	<b>CORRECTING WATER, ELECTROLYTE, AND ACID-BASE DISTURBANCES</b>			
	Oral rehydration salt [for glucose electrolyte solution]	Powder for dilution: in 200 mL: 500 mL and 1 L Composition: Glucose 75 mEq, Sodium 75 mEq or mmol/L, Chloride 65 mEq or mmol/L, Potassium 20 mEq or mmol/L, citrate 10 mmol/L Osmolarity 245 mOsm/L Glucose 13.5 G/L, Sodium Chloride 2.6 G/L, Potassium Chloride 1.5 G/L Trisodium citrate dehydrate 2.9 G/L	<b>P, S, T</b>	Restricted for Health Facilities
	Glucose	Injectable solution: 5 %; 10 % isotonic; 25 %; 50 % hypertonic	<b>P, S, T</b>	<b>POM</b>
	Glucose with sodium chloride	Injectable solution: 4 % glucose, 0.18 % sodium chloride [equivalent to Na <sup>+</sup> 30mmol/L, Cl <sup>-</sup> 30 mmol/L]	<b>P, S, T</b>	<b>POM</b>



	Glucose with sodium chloride	Injectable solution: 5% glucose and 0.9 % sodium chloride [equivalent to Na+ 154mmol/L; Cl- 154mmol/L]	<b>P, S, T</b>	<b>POM</b>
	Glucose with sodium chloride	Injectable solution: 5% glucose, 0.45 % sodium chloride [equivalent to Na+ 154 mmol/L; Cl- 77 mmol/L]	<b>P, S, T</b>	<b>POM</b>
	Potassium chloride	Injectable solution: 11.2 % in 20 ml ampoule [equivalent to K+1,5 mmol/L, Cl-30 mmol/L] Solution for dilution: 7.5 % [equivalent to K+1 mmol/L, 15 % [equivalent to K+ 2mmol/L, Cl-2mmol/L]	<b>P, S, T</b>	Restricted for Health Facilities
	Sodium Chloride	Injectable solution: 0.9 % isotonic [equivalent to Na+ 154 mmol/L; Cl- 154 mmol/L]	<b>P, S, T</b>	Restricted for Health Facilities
	Sodium Chloride	Injectable solution: 3%	<b>P, S, T</b>	Restricted for Health Facilities
	Sodium hydrogen carbonate	Injectable solution 1.4% isotonic [equivalent to Na+167 mmol/L; HCO- 167 mmol/L]	<b>T</b>	Restricted for Health Facilities
	Sodium Lactate; compound solution [Ringer lactate], Injectable solution	<b>Injectable solution</b>	<b>P, S, T</b>	<b>POM</b>
	Water for injection	2 mL; 5 mL; 10 mL ampoule	<b>P, S, T</b>	<b>OTC</b>
<b>27</b>	<b>VITAMINS AND MINERALS</b>			
	Calcitriol	<b>Tablet:</b> 0.25mcg	<b>T</b>	<b>POM</b>
	Cholecalciferol	<b>Oral liquid:</b> 400 IU/mL Solid oral dosage form, granules/sachets: 400 IU; 1000 IU, 60,000IU	<b>T</b>	<b>POM</b>
	Calcium Carbonate	<b>Tablet:</b> 500mg <b>Oral Liquid:</b> 400mg/5ml	<b>P, S, T</b>	<b>POM</b>
	Calcium + Phosphorus + Magnesium + Zinc + Vitamin D	<b>Oral Liquid:</b> 300mg + 150mg + 75mg + 4mg + 200 IU / 10 mL	<b>P, S, T</b>	<b>POM</b>
	Ascorbic acid	<b>Tablet:</b> 100mg, 500 mg	<b>P, S, T</b>	<b>OTC</b>
	Pyridoxine	<b>Tablet:</b> 10mg; 40 mg	<b>P, S, T</b>	<b>POM</b>
	Vitamin A (Retinol)	Sugar-coated <b>Tablet:</b> 10 000 IU [palmitate, 5.5mg];  <b>Capsule:</b> 100,000 IU (30mg Palmitate) stabilized with 20 IU Vitamin E & 200,000	<b>NP</b>	Restricted and to be used for the National program only

		IU (60mg palmitate) stabilized with 20 IU Vitamin E  Oral oily solution: 100 000 IU [palmitate]/mL in multidose dispenser  Water miscible <b>Injection:</b> 100 000 IU [palmitate, 55 mg] in 2 mL ampoule		
	Vitamin B complex	<b>Capsule:</b> Vit B1 1 mg, vit B2 1 mg <b>Tablet:</b> Vitamin B1 + 1 mg, Vitamin B2 + 1 mg <b>Oral liquid</b>	<b>P, S, T</b>	<b>OTC</b>
	Thiamine	<b>Tablet:</b> 50mg, 75 mg  <b>Injection:</b> 100 mg	<b>S, T</b>	<b>POM</b>  Restricted for Health Facilities
	Calcium gluconate	<b>Injection:</b> 100 mg/mL in 10 mL ampoule	<b>P, S, T</b>	Restricted for Health Facilities
	Calcium Polystyrene Sulfonate	15 g Sachet	<b>S, T</b>	<b>POM</b>
<b>28</b>	<b>MEDICINES USED FOR THE EAR, NOSE, AND OROPHARYNX</b>			
<b>28.1</b>	<b>Ear</b>			
<b>28.1.1</b>	<b>Anti-infective agents and anti-infective agents with corticosteroids</b>			
	Clotrimazole	Solution [ear drop]	<b>P, S, T</b>	<b>POM</b>
	Clotrimazole + hydrocortisone	Solution [ear drop]: 1%  Cream: 1%	<b>P, S, T</b>	<b>POM</b>
	Ciprofloxacin <small>watch group antibiotic.</small>	Solution eye/ear drop: 0.3 %, Eye/ear ointment: 0.3%v	<b>P, S, T</b>	<b>POM</b>
<b>28.1.2</b>	<b>Medicines for vestibular disorder</b>			
	Cinnarizine	<b>Tablet:</b> 5 mg; 25 mg	<b>P, S, T</b>	<b>POM</b>
	Prochlorperazine	<b>Injection:</b> 12.5 mg/mL ampoule	<b>P, S, T</b>	<b>POM</b>
<b>28.2</b>	<b>Nose</b>			
<b>28.2.1</b>	<b>Corticosteroids</b>			
	Beclomethasone	Solution for nasal spray	<b>P, S, T</b>	<b>POM</b>
<b>28.2.2</b>	<b>Decongestants</b>			
	Oxymetazoline	Solution for Nose drops: 0.05%; 0.025 %	<b>P, S, T</b>	<b>POM</b>
	Normal saline	Solution for nasal use: 0.9 %	<b>P, S, T</b>	<b>POM</b>
<b>28.2.3</b>	<b>Local anaesthetics</b>			
	Lidocaine	Spray: 4 %	<b>S, T</b>	Restricted for Health Facilities

	Lidocaine + Prilocaine	Cream: 5%	P, S, T	<b>POM</b>
<b>29</b>	<b>SPECIFIC MEDICINES FOR NEONATAL CARE</b>			
	Caffein citrate	<b>Oral liquid:</b> 20 mg/mL (equivalent to base 10mg/mL) <b>Injection:</b> 10mg/ml	<b>S, T</b>	<b>POM</b>
	Ibuprofen	<b>Injection:</b> 5 mg/mL	<b>P, S, T</b>	<b>POM + Restricted for Health Facilities</b>
	Prostaglandins	Prostaglandin E2: 1 mg/mL; Prostaglandin E1: 0.5 mg/mL	<b>S, T</b>	<b>Restricted for Health Facilities</b>
	Surfactant	Suspension for intra-tracheal instillation: 25mg/mL; 80 mg/mL	<b>S, T</b>	<b>POM + Hospital use only</b>
	Aminophylline	<b>Injection:</b> 25 mg/mL in 10 mL ampoule	<b>S, T</b>	<b>Restricted for Health Facilities</b>
	Intralipid for total parenteral nutrition	Solution: 20 % {TPN}	<b>S, T</b>	<b>Restricted for Health Facilities</b>
	Amino acid	Infant solution: 10 %	<b>T</b>	<b>Restricted for Health Facilities</b>
	Human milk fortifier	Sachets	<b>S, T</b>	<b>POM</b>
<b>30</b>	<b>MEDICINES FOR BONES AND JOINTS</b>			
	Alendronate	<b>Tablet:</b> 70 mg	<b>S, T,</b>	<b>POM</b>
	Zoledronate	<b>Injection:</b> 4mg/5mL, 5mg	<b>S, T</b>	<b>POM</b>
	Denosumab	<b>Injection:</b> 60mg/vial	<b>S, T</b>	<b>Restricted for Health Facilities</b>
<b>31</b>	<b>DENTAL MEDICINES AND PREPARATIONS</b>			
	Lidocaine	<b>Oral gel:</b> 2%	<b>P, S, T</b>	<b>POM</b>
	Triamcinolone	<b>Injection:</b> 10mg, 20mg, 40mg/mL in a vial <b>Oral gel/paste:</b> 0.1%	<b>P, S, T</b>	<b>POM</b>

**Table 1. Description of where medicine must be made available (Grade Level Categorization)**

<b>A</b>	These medicines MUST be made available in all registered pharmacies.	PHARMACY
<b>B</b>	Pharmacies located on islands served by Health Centre Grade 4 (HCG4), Hospital Grade 1 (HG1), Hospital Grade 2 (HG2), Hospital Grade 3 (HG3), and tertiary-level Health Facilities MUST make available all medicines listed in this category.	
<b>C</b>	Pharmacies located on islands served by Health HG3 and tertiary-level health facilities must be required to make all medicines listed in this category available.	
<b>D</b>	These medicines MUST be made available in all registered Health Facilities, including the private sector.	HEALTH FACILITIES
<b>E</b>	These medicines MUST be made available in HG1, HG2, and HCG4 Health Facilities, as well as in tertiary and HG3 facilities, based on the services available.	
<b>F</b>	These medicines MUST be made available in Tertiary and HG3 settings, based on the services available.	

**\* Hospitals and Private clinics must adhere to the mandated medicines in-house, as per the registration and licensing requirements of the Ministry of Health.**

The list below is organized by the level of Pharmacies and Health Care Facilities for easier identification.

Medicine / Product	Dosage Form and Strengths	Level of Care	Schedules	Grade Level
Acetazolamide	<b>Tablet:</b> 250 mg	P, S, T	POM	A
Acetyl salicylic acid	<b>Tablet:</b> 75 mg; 100mg; 150 mg; 300 mg	P, S, T	POM	A
Acetylcysteine	<b>Tablet:</b> 600 mg	P, S, T	POM	A
Acyclovir	<b>Tablet:</b> 200 mg; 400 mg; 800 mg	P, S, T	POM	A
Acyclovir	<b>Oral Liquid:</b> 200 mg/5mL	P, S, T	POM	A
Acyclovir	<b>Cream:</b> 3 %, 5 %	P, S, T	POM	A
Acyclovir	<b>Ointment:</b> 3 %	P, S, T	POM	A
Acyclovir	<b>Injection:</b> 250mg [sodium salt] in vial	P, S, T	POM	A
Albendazole	<b>Oral liquid:</b> 200 mg/5mL	P, S, T	OTC	A
Albendazole	<b>Tablet:</b> 200 mg; 400 mg	P, S, T	OTC	A
Aluminium Magnesium based antacid	<b>Tablet:</b> 200 mg + 200 mg; 400 mg + 400 mg	P, S, T	POM	A
Aluminium Magnesium based antacid	<b>Oral liquid:</b> 40mg /mL + 40 mg/mL	P, S, T	POM	A
Amantadine	<b>Tablet:</b> 100mg	P, S, T	POM	A
Amikacin <sup>access group antibiotic</sup>	<b>Injection:</b> 250mg [as sulphate] in vial	P, S, T	POM	A
Amikacin <sup>access group antibiotic</sup>	Powder for <b>Injection:</b> 1 g in vial	P, S, T	POM	A
Amiodarone	<b>Tablet:</b> 100 mg; 200 mg	P, S, T	POM	A
Amitriptyline	<b>Tablet:</b> 10mg; 25 mg [HCl]	P, S, T	POM	A
Amlodipine	<b>Tablet:</b> 2.5 mg; 5 mg	P, S, T	POM	A
Amoxicillin + clavulanic acid <sup>access group antibiotic</sup>	<b>Oral liquid:</b> 228mg/5ml (200mg + 28mg/5ml).	P, S, T	POM	A
Amoxicillin + clavulanic acid <sup>access group antibiotic</sup>	<b>Oral drop:</b> 62.5 mg/mL	P, S, T	POM	A
Amoxicillin + clavulanic acid <sup>access group antibiotic</sup>	<b>Tablet:</b> 625 mg; 375 mg	P, S, T	POM	A
Amoxicillin <sup>access group antibiotic</sup>	Capsule: 250 mg; 500 mg (anhydrous	P, S, T	POM	A
Amoxicillin <sup>access group antibiotic</sup>	Powder for oral suspension: 125 mg (anhydrous)/5 mL	P, S, T	POM	A
Ampicillin <sup>access group antibiotic</sup>	<b>Tablet/Capsule:</b> 500 mg	P, S, T	POM	A
Artificial tears		P, S, T	OTC	A
Ascorbic acid	<b>Tablet:</b> 500 mg	P, S, T	OTC	A
Atomoxetine	<b>Tablet:</b> 10mg, 18mg, 25mg	P, S, T	POM	A
Atorvastatin	<b>Tablet:</b> 10mg; 20 mg	P, S, T	POM	A
Atropine	<b>Eye Drops:</b> 1%	P, S, T	POM	A
Azathioprine	<b>Tablet:</b> 50 mg	S, T	POM	A
Azithromycin <sup>watch group antibiotic</sup>	<b>Tablet:</b> 250 mg; 500mg	P, S, T	POM	A
Azithromycin <sup>watch group antibiotic</sup>	<b>Oral liquid:</b> 100g/5ml	P, S, T	POM	A
Baclofen	<b>Tablet:</b> 10mg	P, S, T	POM	A

Beclomethasone	Inhalation [aerosol] 50 microgram per dose [dipropionate]; 250 microgram per dose [dipropionate]	P, S, T	POM	A
Beclomethasone	Solution for nasal spray	P, S, T	POM	A
Beclomethasone + Salicylic acid	Ointment: 0.1% + 3% w/w	P, S, T	POM	A
Betamethasone	<b>Ointment/Cream:</b> 0.1 %; 0.05% [dipropionate]	P, S, T	POM	A
Betamethasone	<b>Tablet:</b> 0.5mg	P, S, T	POM	A
Bisacodyl	<b>Tablet:</b> 5mg	P, S, T	POM	A
Bisacodyl	<b>Suppository:</b> 10mg	P, S, T	POM	A
Calcipotriol	Ointment: 0.005%	P, S, T	POM	A
Calcitriol	<b>Tablet:</b> 0.25mcg	P, S, T	POM	A
Calcium + Phosphorus + Magnesium + Zinc + Vitamin D	<b>Oral Liquid:</b> 300mg + 150mg + 75mg + 4mg + 200 IU / 10 mL	P, S, T	POM	A
Calcium Carbonate	<b>Tablet:</b> 500mg	P, S, T	POM	A
Calcium Carbonate	<b>Oral Liquid:</b> 400mg/5ml	P, S, T	POM	A
Carbamazepine	<b>Oral liquid:</b> 100 mg/5mL,	P, S, T	POM	A
Carbamazepine	<b>Tablet:</b> 100mg, 200mg	P, S, T	POM	A
Carbimazole	<b>Tablet</b> [film coated]: 5 mg; 10mg	P, S, T	POM	A
Cetirizine	<b>Oral liquid:</b> 5 mg/5 mL	P, S, T	OTC	A
Cetirizine	<b>Tablet:</b> 10mg	P, S, T	OTC	A
Charcoal, Activated	<b>Powder:</b> 50 g cans or pack	P, S, T	POM	A
Chloramphenicol <small>access group antibiotic</small>	<b>Capsule:</b> 250 mg	P, S, T	POM	A
Chloramphenicol <small>access group antibiotic</small>	Oral suspension: 125 mg/5mL [palmitate]	P, S, T	POM	A
Chlorhexidine	<b>Solution:</b> 5 % (digluconate)	P, S, T	OTC	A
Chlorpheniramine maleate	<b>Oral liquid:</b> 2 mg/5 mL;	P, S, T	POM	A
Chlorpheniramine maleate	<b>Tablet:</b> 4 mg [hydrogen maleate]	P, S, T	POM	A
Chlorpromazine	<b>Oral liquid:</b> 25mg/5mL [HCL]	P, S, T	POM	A
Chlorpromazine	<b>Tablet:</b> 100mg [HCL]	P, S, T	POM	A
Cholecalciferol	<b>Oral liquid:</b> 400 IU/mL	P, S, T	POM	A
Cholecalciferol	<b>Solid oral dosage form: granules/sachets:</b> 400 IU; 1000 IU, 60,000IU	P, S, T	POM	A
Cinnarizine	<b>Tablet:</b> 5 mg; 25 mg	P, S, T	POM	A
Clobetasol Propionate	<b>Cream:</b> 0.05% w/w	P, S, T	POM	A
Clobetasol Propionate	<b>Ointment:</b> 0.05% w/w	P, S, T	POM	A
Clopidogrel	<b>Tablet:</b> 75 mg	P, S, T	POM	A
Clotrimazole	<b>Vaginal tablets:</b> 100 mg; 200 mg	P, S, T	POM	A
Clotrimazole	<b>Gel:</b> 1 %; 10 %	P, S, T	POM	A
Clotrimazole	<b>Cream:</b> 1 %; 2 %	P, S, T	POM	A
Clotrimazole	Solution: 1% ear drop	P, S, T	POM	A
Clotrimazole + hydrocortisone	Solution [ear drop]: 1%	P, S, T	POM	A
Clotrimazole + hydrocortisone	<b>Cream:</b> 1%	P, S, T	POM	A
Desonide	<b>Lotion:</b> 0.05%	P, S, T	POM	A
Dexamethasone	<b>Eye drop:</b> 0.1%	P, S, T	POM	A
Diazepam	<b>Tablet:</b> 1mg, 2mg, 5mg, 10mg	P, S, T	Controlled	A
Diazepam	<b>Oral liquid:</b> 2 mg/5mL	P, S, T	Controlled	A
Diazepam	<b>Rectal solution:</b> 2.5.mg; 5 mg; 10mg	P, S, T	Controlled	A
Diclofenac sodium	<b>Tablet:</b> 25 mg; 50 mg	P, S, T	POM	A
Diclofenac sodium	<b>Suppository:</b> 12.5 mg; 50 mg	P, S, T	POM	A
Dobutamine	<b>Injection:</b> 250 mg/5mL, 250mg/20ml	P, S, T	POM	A
Domperidone	<b>Tablet:</b> 10mg	P, S, T	POM	A
Domperidone	<b>Oral liquid:</b> 5 mg/5mL	P, S, T	POM	A
Doxycycline <small>access group antibiotic</small>	Capsule or Tablet:100 mg (hydrochloride)	P, S, T	POM	A
Duloxetine	<b>Tablet:</b> 20mg	P, S, T	POM	A
Dydrogesterone	<b>Tablet:</b> 10mg	P, S, T	POM	A
Elemental Zinc [sulphate]	<b>Tablet:</b> 10mg per unit dosage form	P, S, T	POM	A
Elemental Zinc [sulphate]	<b>Oral liquid:</b> 10mg per unit dosage form	P, S, T	POM	A
Empagliflozin	<b>Tablet:</b> 10mg, 25mg	P, S, T	POM	A
Enalapril	<b>Tablet:</b> 2.5 mg; 5 mg	P, S, T	POM	A
Enalapril	<b>Injection:</b> 1.25/mL	P, S, T	POM	A
Eplerenone	<b>Tablet:</b> 25mg	P, S, T	POM	A
Escitalopram	<b>Tablet:</b> 5 mg; 10mg	P, S, T	POM	A
Estradiol	<b>Tablet:</b> 10 mcg; 50 mcg, 2mg	P, S, T	POM	A
Ethanol	<b>Solution:</b> 70% (denatured)	P, S, T	POM	A

Ferrous salt	<b>Oral solution:</b> equivalent to 25 mg elemental iron [as sulphate]/mL	P, S, T	POM	A
Ferrous salt	<b>Tablet:</b> equivalent to 60 mg iron	P, S, T	POM	A
Ferrous Salt + folic acid	<b>Tablet:</b> equivalent to 60 mg iron + 400 mcg	P, S, T	POM	A
Fexofenadine	<b>Tablet:</b> 120 mg, 180 mg	P, S, T	OTC	A
Fexofenadine	<b>Syrup:</b> 30mg/5ml	P, S, T	OTC	A
Flucloxacillin <small>access group antibiotic</small>	<b>Tablet/Capsule:</b> 250mg; 500mg	P, S, T	POM	A
Fluconazole	Tablet or <b>Capsule:</b> 50 mg; 100 mg; 150 mg	P, S, T	POM	A
Fluconazole	Oral suspension: 50 mg/5mL	P, S, T	POM	A
Fluconazole	Eye drop: 0.3 %	P, S, T	POM	A
Fluorescein	Eye drops: 1% (sodium salt)	P, S, T	POM	A
Fluoxetine	<b>Capsule:</b> 10mg, 20 mg.	P, S, T	POM	A
Fluoxetine	Syrup: 20 mg/5mL	P, S, T	POM	A
Fluphenazine	Injection/Depot: 25 mg decanoate or enanthate in 1 mL ampoule	P, S, T	POM	A
Fluticasone	<b>Cream:</b> 0.05%	P, S, T	POM	A
Fluticasone	<b>Ointment:</b> 0.005%	P, S, T	POM	A
Folic acid	<b>Tablet:</b> 1 mg; 5 mg,	P, S, T	POM	A
Folic acid	<b>Oral Liquid:</b> 2.5mg/5ml, 5 mg/ 5 ml	P, S, T	POM	A
Furosemide	<b>Injection:</b> 10mg/mL in 2 mL ampoule	P, S, T	POM	A
Furosemide	<b>Syrup:</b> 20mg/5mL, 50mg/5mL	P, S, T	POM	A
Furosemide	<b>Tablet:</b> 20 mg; 40 mg	P, S, T	POM	A
Fusidic acid	<b>Cream:</b> 2%	P, S, T	POM	A
Fusidic acid	<b>Ointment:</b> 2 %	P, S, T	POM	A
Glimepiride	<b>Tablet:</b> 1 mg; 2 mg	P, S, T	POM	A
Glycerin	<b>Suppository:</b> paediatric; adult	P, S, T		A
Glyceryl trinitrate	<b>Tablet sublingual:</b> 500 microgram	P, S, T	POM	A
Griseofulvin	Tablet or <b>Capsule:</b> 125 mg; 250 mg	P, S, T	POM	A
Haloperidol	<b>Tablet:</b> 0.25mg, 1.5mg, 2mg; 5mg <b>Drops:</b> 2mg/ml	P, S, T	POM	A
Hydrochlorothiazide	<b>Tablet:</b> 25 mg; 12.5 mg	P, S, T	POM	A
Hydrocortisone	<b>Tablet:</b> 5mg, 10mg	P, S, T	POM	A
Hydrocortisone	<b>Topical:</b> 0.5 %; 1 % [acetate]	P, S, T	POM	A
Hyoscine butyl bromide	Tablet: 10mg	P, S, T	POM	A
Ibuprofen	<b>Oral liquid:</b> 100 mg/5 mL	P, S, T	POM	A
Ibuprofen	<b>Tablet:</b> 200 mg; 400 mg	P, S, T	OTC	A
Ibuprofen	<b>Injection:</b> 5mg/ml,	P, S, T	POM	A
Imipramine	<b>Tablet:</b> 25 mg	P, S, T	POM	A
INSULIN aspart	<b>Pen:</b> 100 IU/mL	P, S, T	POM	A
Insulin Detemir	<b>Pen:</b> 100 IU/mL	P, S, T	POM	A
Insulin Glargine	<b>Pen:</b> 100 IU/mL	P, S, T	POM	A
Insulin injection [soluble]	<b>Injection:</b> 100 IU/mL in 10 mL vial	P, S, T	POM	A
Insulin injection [soluble]	<b>Pen:</b> 100 IU/mL	P, S, T	POM	A
Intermediate acting insulin [human]	<b>Pen:</b> 100 IU/mL	P, S, T	POM	A
Ipratropium bromide	<b>Inhalation [aerosol]:</b> 20microgram/metered dose	P, S, T	POM	A
Isosorbide dinitrate	<b>Tablet sublingual:</b> 5 mg; 10mg	P, S, T	POM	A
Isosorbide mononitrate	<b>Tablet:</b> 10mg, 20mg	P, S, T	POM	A
Ivermectin	<b>Tablet:</b> 3mg	P, S, T	POM	A
Ketoconazole	<b>Cream:</b> 2%	P, S, T	POM	A
Lactulose	<b>Oral suspension</b>	P, S, T	OTC	A
Lansoprazole	<b>Oral liquid:</b> 3mg/ml	P, S, T	POM	A
Levonorgestrel	<b>Tablet:</b> 0.75 mg, 1.50mg	P, S, T	POM	A
Levonorgestrel + Ethinylestradiol	<b>Tablet:</b> 0.15mg + 0.03mg	P, S, T	POM	A
Levothyroxine	<b>Tablet:</b> 25 micrograms; 50 micrograms; 75 microgram; 100 micrograms [sodium salt]	P, S, T	POM	A
Lidocaine + Prilocaine	<b>Cream:</b> 5%	P, S, T	POM	A
Lorazepam	<b>Tablet:</b> 1 mg; 2 mg	P, S, T	Controlled	A
Losartan [potassium]	<b>Tablet:</b> 25 mg; 50 mg	P, S, T	POM	A
Mebendazole	<b>Tablet:</b> 100 mg	P, S, T	OTC	A
Mebendazole	<b>Syrup:</b> 100 mg/5mL	P, S, T	OTC	A
Mefenamic acid	<b>Tablet:</b> 250 mg; 500 mg	P, S, T	OTC	A
Metformin	<b>Tablet:</b> 500 mg; 850 mg; 1000 mg SR [HCl]	P, S, T	POM	A

Methylprednisolone	<b>Tablet:</b> 2 mg; 4 mg	P, S, T	POM	A
Metoclopramide	<b>Tablet:</b> 10mg (hydrochloride)	P, S, T	POM	A
Metoclopramide	<b>Syrup:</b> 5mg/5ml	P, S, T	POM	A
Metoprolol	<b>Tablet:</b> 25 mg; 50	P, S, T	POM	A
Metronidazole <small>access group antibiotic</small>	<b>Tablet:</b> 200 mg, 400 mg	P, S, T	POM	A
Metronidazole <small>access group antibiotic</small>	<b>Oral suspension:</b> 100 mg (as benzoate)/5 ml	P, S, T	POM	A
Metronidazole <small>access group antibiotic</small>	<b>Gel:</b> 0.75 %	P, S, T	POM	A
Mirtazapine	<b>Tablet:</b> 15 mg	P, S, T	POM	A
Mupirocin	<b>Cream:</b> 2% (as calcium)	P, S, T	POM	A
Mupirocin	<b>Ointment:</b> 2%	P, S, T	POM	A
Mycophenolate mofetil	<b>Tablet:</b> 500 mg; 360 mg	P, S, T	POM	A
Nepafenac	<b>Eye drop:</b> 0.1%	P, S, T	POM	A
Nicotine Replacement Therapy [NRT]	<b>Chewing gum:</b> 2mg, 4mg [as polacrilex]	P, S, T	POM	A
Nicotine Replacement Therapy [NRT]	<b>Transdermal patch:</b> 7mg, 14mg, 21mg	P, S, T	POM	A
Nitrofurantoin <small>access group antibiotic</small>	<b>Tablet/Capsule:</b> 100mg	P, S, T	POM	A
Norgestrel + Ethinylestradiol	<b>Tablet:</b> 0.5mg + 0.05mg	P, S, T	POM	A
Normal saline	Solution for nasal use: 0.9 %	P, S, T	POM	A
Ofloxacin	<b>Tablet:</b> 100 mg; 200 mg; 400 mg	P, S, T	POM	A
Ofloxacin <small>watch group antibiotic</small>	<b>Eye solution:</b> 0.3%	S, T	POM	A
Olopatadine	Eye solution: 0.1 %	P, S, T	POM	A
Ondansetron	<b>Syrup:</b> 2 mg/5mL, 4mg/5ml	P, S, T	POM	A
Oral rehydration salt [for glucose electrolyte solution]	Powder for dilution: in 200 mL: 500 mL and 1 L Composition: Glucose 75 mEq, Sodium 75 mEq or mmol/L, Chloride 65 mEq or mmol/L, Potassium 20 mEq or mmol/L, citrate 10 mmol/L, Osmolarity 245 mOsm/L, Glucose 13.5 G/L, Sodium Chloride 2.6 G/L, Potassium Chloride 1.5 G/L, Trisodium citrate dehydrate 2.9 G/L	P, S, T	OTC	A
Oseltamivir	<b>Capsule:</b> 30 mg; 45 mg; 75 mg	P, S, T	POM	A
Oseltamivir	<b>Oral liquid:</b> 12 mg/mL	P, S, T	POM	A
Oxygen	<b>Inhalation</b> (medical gas)	P, S, T	POM	A
Oxymetazoline	Solution for Nose drops: 0.05%; 0.025 %	P, S, T	POM	A
Pantoprazole	<b>Tablet:</b> 20 mg; 40 mg	P, S, T	POM	A
Pantoprazole	Oral liquid: 2mg/ml	P, S, T	POM	A
Paracetamol	<b>Oral Drops:</b> 100 mg/ml	P, S, T	OTC	A
Paracetamol	<b>Suppository:</b> 125 mg; 250 mg	P, S, T	OTC	A
Paracetamol	<b>Oral liquid:</b> 120 mg/5 mL; 250 mg/5 mL	P, S, T	OTC	A
Permethrin	Cream/lotion: 5 % [for scabies]	S, T	OTC	A
Pheniramine	<b>Tablet:</b> 25mg,	P, S, T	POM	A
Pheniramine	<b>Syrup:</b> 15 mg/5ml,	P, S, T	POM	A
Phenobarbital	<b>Oral liquid:</b> 20 mg/5mL	P, S, T	Controlled	A
Phenobarbital	<b>Tablet:</b> 30 mg; 60 mg	P, S, T	Controlled	A
Phenoxyethylpenicillin or penicillin <small>access group antibiotic</small>	<b>Tablet:</b> 250 mg; 500 mg	P, S, T	POM	A
Phenoxyethylpenicillin or penicillin <small>access group antibiotic</small>	<b>Syrup:</b> 125 mg/5mL	P, S, T	POM	A
Phenytoin sodium	<b>Oral liquid:</b> 25 mg – 30mg per 5 mL	P, S, T	POM	A
Phenytoin sodium	<b>Tablet:</b> 25 mg, 50 mg, and 100 mg [sodium salt]	P, S, T	POM	A
Prednisolone	<b>Tablet:</b> 5 mg; 20 mg	P, S, T	POM	A
Prednisolone	<b>Oral liquid:</b> 5 mg/5mL	P, S, T	POM	A
Prednisolone	<b>Tablet:</b> 5mg; 20mg	P, S, T	POM	A
Promethazine	<b>Oral liquid:</b> 5mg [HCl]/5ml	P, S, T	POM	A
Promethazine	<b>Tablet:</b> 10mg; 25mg [HCl]	P, S, T	POM	A
Proparacaine	Eye Drops: 0.5%	P, S, T	Restricted for Health Facilities	A
Propranolol	<b>Tablet:</b> 5mg; 10mg; 40 mg	P, S, T	POM	A
Pyridoxine	<b>Tablet:</b> 10mg; 40 mg	P, S, T	POM	A
Ranitidine	<b>Oral liquid:</b> 75 mg/5mL	P, S, T	POM	A
Ranitidine	<b>Tablet:</b> 150 mg	P, S, T	POM	A
Risperidone	<b>Tablet:</b> 1mg, 2mg	S, T	POM	A

Risperidone	<b>Oral liquid:</b> 1mg/ml	S, T	POM	A
Rosuvastatin	<b>Tablet:</b> 10mg and 20mg	P, S, T	POM	A
Rota Virus vaccine		P, S, T	POM	A
Salbutamol	Inhalation [aerosol]:100 microgram per dose [as sulphate]	P, S, T	POM	A
Salbutamol	<b>Tablet:</b> 2 mg; 4 mg	P, S, T	POM	A
Sertraline	<b>Tablet:</b> 50mg, 100mg	S, T	POM	A
Silver Sulfadiazine	<b>Cream:</b> 1 %	P, S, T	POM	A
Simethicone	<b>Tablet:</b> 80mg, 140mg	P, S, T	POM	A
Simethicone	<b>Drop:</b> 20mg	P, S, T	POM	A
Simethicone	<b>Oral liquid:</b> 2 % emulsion	P, S, T	POM	A
Sitagliptin	<b>Tablet:</b> 50 mg	S, T	POM	A
Sodium Valproate (Valproic acid)	<b>Tablet:</b> 200mg, 500mg (enteric coated)	P, S, T	POM	A
Sodium Valproate (Valproic acid)	<b>Oral liquid:</b> 200mg/5ml	P, S, T	POM	A
Spiramycin	<b>Tablet:</b> 1.5 million IU; 3 million IU	P, S, T	POM	A
Spironolactone	<b>Tablet:</b> 25 mg; 50 mg	P, S, T	POM	A
Sulfamethoxazole + Trimethoprim access group antibiotic	Tablet: 400 mg + 80 mg	P, S, T	POM	A
Sulfamethoxazole + Trimethoprim access group antibiotic	Oral suspension: 200 mg + 40 mg/5 mL	P, S, T	POM	A
Tacrolimus	<b>Tablet:</b> 1 mg; 2 mg	P, S, T	POM	A
Tacrolimus	Ointment: 0.03 %; 0.1 %	P, S, T	POM	A
Theophylline	Tablet/ <b>Capsule:</b> 100 mg; 200 mg; 300 mg	P, S, T	POM	A
Theophylline	Syrup : 80 mg/15 mL	P, S, T	POM	A
Timolol	Solution/eye drop: 0.25 %; 0.5 % [maleate]	P, S, T	POM	A
Tobramycin	Eye drop/ointment	P, S, T	POM	A
Torsemide	<b>Tablet:</b> 10mg, 20mg	P, S, T	POM	A
Tretinoin	Cream 0.025 %	P, S, T	POM	A
Triamcinolone	<b>Oral Gel/Paste:</b> 0.1%	P, S, T	POM	A
Triamcinolone	<b>Injection:</b> 10mg, 20mg, 40mg/mL in vial	P, S, T	POM	A
Trihexyphenidyl HCl	<b>Tablet:</b> 2 mg	P, S, T	POM	A
Tropicamide	Eye drop: 0.5 %; 0.1%	P, S, T	POM	A
Ursodeoxycholic acid	<b>Tablet:</b> 150 mg; 300 mg	P, S, T	POM	A
Valproic acid (Sodium Valproate)	<b>Oral liquid:</b> 200mg/5 mL	P, S, T	POM	A
Valproic acid (Sodium Valproate)	<b>Tablet enteric coated:</b> 200 mg; 500 mg [sodium salt]	P, S, T	POM	A
Verapamil	<b>Tablet:</b> 40 mg; 80 mg [HCl]	P, S, T	POM	A
Vitamin B complex	<b>Capsule:</b> Vit B1 1 mg, vit B2 1 mg	P, S, T	OTC	A
Vitamin B complex	<b>Tablet:</b> VitB1 1 mg, Vita B2 1 mg	P, S, T	OTC	A
Warfarin	<b>Tablet:</b> 1 mg; 2 mg, 3mg, 4mg, and 5 mg (sodium salt)	S, T	POM	A
Dexamethasone	<b>Tablet:</b> 0.5 mg	P, S, T	POM	A
Amiodarone	<b>Injection:</b> 25mg/ml in 3ml	P, S, T	POM	A, D
Amoxicillin + clavulanic acid access group antibiotic	<b>Powder for injection:</b> 600 mg, 1.2 g in vial.	P, S, T	POM	A, D
Ampicillin access group antibiotic	<b>Powder for injection:</b> 500 mg; 1 g (as sodium salt) in vial.	P, S, T	POM	A, D
Betamethasone	<b>Injection:</b> 6 mg/mL	P, S, T	POM	A, D
Chlorpheniramine maleate	<b>Injection:</b> 10mg [ hydrogen maleate] in 1 – mL ampoule;	P, S, T	POM	A, D
Dexamethasone	<b>Injection:</b> 4 mg dexamethasone phosphate [as disodium salt] in 1 mL-ampoule	P, S, T	POM	A, D
Diazepam	<b>Injection:</b> 5 mg/mL	P, S, T	Controlled	A, D
Diclofenac sodium	<b>Injection:</b> 75mg/5ml	P, S, T	POM	A, D
Gentamycin access group antibiotic	Injection:10mg; 40 mg (as sulfate)/ml in 2-ml vial	P, S, T	POM	A, D
Glucose	Injectable solution: 5 %; 10 % isotonic; 25 %; 50 % hypertonic	P, S, T	POM	A, D
Glucose with sodium chloride	Injectable solution: 5% glucose and 0.9 % sodium chloride [equivalent to Na+ 154mmol/L ; Cl- 154mmol/L]	P, S, T	POM	A, D



Glucose with sodium chloride	Injectable solution: 5% glucose, 0.45 % sodium chloride [equivalent to Na+ 154 mmol/L; Cl- 77 mmol/L]	P, S, T	POM	A, D
Glyceryl trinitrate	Injection: 5 mg/ml ,	P, S, T	POM	A, D
Haloperidol	Injection: 5mg in 1mL ampoule, Depot: 50mg/ml	P, S, T	POM	A, D
Heparin sodium	<b>Injection:</b> 1000 IU/mL; 2000 IU/mL in 2 mL ampoule	P, S, T	POM	A, D
Hydrocortisone	Powder for <b>Injection:</b> 100 mg/mL [sodium]	P, S, T	POM	A, D
Hyoscine butyl bromide	<b>Injection:</b> 20 mg/mL	P, S, T	POM	A, D
Ipratropium bromide	<b>SOULTION</b>	P, S, T	POM	A, D
Lidocaine	<b>Injection:</b> 2 mg [HCl]/mL in 5 mL ampoule	P, S, T	POM	A, D
Lorazepam	<b>Injection:</b> 1 mg/ml, 2mg/ml	P, S, T	Controlled	A, D
Mannitol	<b>Injectable solution:</b> 10 %; 20 %	P, S, T	POM	A, D
Metoclopramide	<b>Injection:</b> 5 mg (hydrochloride)/ml in 2-ml ampoule	P, S, T	POM	A, D
Metoprolol	<b>Injection :</b> 5mg	P, S, T	POM	A, D
Metronidazole <small>access group antibiotic</small>	<b>Injection:</b> 500 mg	P, S, T	POM	A, D
Ondansetron	<b>Injection:</b> 2mg/mL in 2 mL ampoule	P, S, T	POM	A, D
Ondansetron	<b>Tablet:</b> 4 mg; 8 mg	P, S, T	POM	A, D
Pantoprazole	<b>Injection:</b> 40 mg in a vial	P, S, T	POM	A, D
Paracetamol	<b>Tablet:</b> 500 mg	P, S, T	OTC	A, D
Paracetamol	<b>Injection:</b> 100 mg/mL, 150 mg/mL	P, S, T	POM	A, D
Pheniramine	<b>Injection:</b> 25mg/ml	P, S, T	POM	A, D
Phenobarbital	<b>Injection:</b> 200 mg/mL	P, S, T	Controlled	A, D
Phenytoin sodium	<b>Injection:</b> 50 mg/mL [sodium salt] in 5 mL vial	P, S, T	POM	A, D
Prochlorperazine	<b>Injection:</b> 12.5 mg/mL ampoule	P, S, T	POM	A, D
Promethazine	<b>Injection:</b> 25mg [HCl]/mL	P, S, T	POM	A, D
Ranitidine	<b>Injection:</b> 25 mg/mL in 2 mL ampoule	P, S, T	POM	A, D
Salbutamol	<b>Injection:</b> 0.5 mg/mL [as sulphate],	P, S, T	POM	A, D
Salbutamol	Respirator solution for nebulizer: 5mg,	P, S, T	POM	A, D
Sodium Chloride	Injectable solution: 0.9 % isotonic [equivalent to Na+ 154 mmol/L; Cl- 154 mmol/L]	P, S, T	Restricted for Health Facilities	A, D
Sodium Chloride	<b>Injectable solution:</b> 3%	P, S, T	Restricted for Health Facilities	A, D
Sodium Lactate; compound solution [Ringer lactate], Injectable solution	<b>Injectable solution</b>	P, S, T	POM	A, D
Sodium phosphate mono hydrate	Disposable enema	P, S, T	POM	A, D
Tramadol	<b>Capsule:</b> 50 mg	P, S, T	Controlled	A, D
Tramadol	<b>Tablet:</b> 50 mg, 100mg (ER)	P, S, T	Controlled	A, D
Tramadol	<b>Oral Liquid:</b> 10mg/ml	P, S, T	Controlled	A, D
Water for injection	2 mL; 5 mL; 10 mL ampoule	P, S, T	OTC	A, D
Lidocaine	Oral gel: 2%	P, S, T	POM	A, D
Alendronate	<b>Tablet:</b> 70 mg	S, T	POM	B
Allopurinol	<b>Tablet:</b> 100 mg	S, T	POM	B
Amisulpride	<b>Tablet:</b> 50mg, 100mg	S, T	POM	B
Aripiprazole	<b>Tablet:</b> 5mg, 10mg, 20mg	S, T	POM	B
Baclofen	<b>Oral liquid:</b> 10mg/5ml	S, T	POM	B
Benzoyl peroxide	<b>Lotion and gel:</b> 2.5 %; 5 %	S, T	POM	B
Caffeine citrate	<b>Oral liquid:</b> 20 mg/mL [equivalent to base 10mg/mL]	S, T	POM	B
Carvedilol	<b>Tablet:</b> 3.125 mg; 6.25 mg, 25mg	S, T	POM	B
Cefadroxil <small>watch group antibiotic</small>	<b>Tablet/Capsule:</b> 250mg; 500mg	S, T	POM	B
Cefadroxil <small>watch group antibiotic</small>	<b>Syrup:</b> 125mg/5ml, 250mg/5ml	S, T	POM	B
Cefixime <small>watch group antibiotic</small>	<b>Tablet:</b> 100mg; 200mg; 400mg.	S, T	POM	B
Cefixime <small>watch group antibiotic</small>	<b>Syrup:</b> 50mg/5mL	S, T	POM	B
Cefuroxime <small>watch group antibiotic</small>	<b>Tablets:</b> 125 mg; 250mg (as cefuroxime axetile)	S, T	POM	B
Cefuroxime <small>watch group antibiotic</small>	<b>Oral Suspension:</b> 125 mg/5 ml	S, T	POM	B
Cefuroxime <small>watch group antibiotic</small>	<b>Injections:</b> 250 mg; 500 mg, 1000 mg	S, T	POM	B
Ciprofloxacin <small>watch group antibiotic</small>	<b>Tablet:</b> 250 mg; 500mg (as hydrochloride),	S, T	POM	B
Ciprofloxacin <small>watch group antibiotic</small>	<b>Suspension:</b> 250mg/5ml	S, T	POM	B

Maldives Food and Drug Authority  
Medicine and Therapeutic Goods Division

Ciprofloxacin <small>watch group antibiotic</small>	Eye drop/ointment: 0.3 %	S, T	POM	B
Ciprofloxacin <small>watch group antibiotic</small>	Solution eye/ear drop: 0.3 %,	S, T	POM	B
Clomiphene	<b>Tablet:</b> 25 mg; 50 mg; 100 mg	S, T	POM	B
Clonazepam	<b>Tablet:</b> 0.5mg; 2mg	S, T	Controlled	B
Clonidine	<b>Tablet:</b> 75mcg, 100mcg, 150 mcg	S, T	POM	B
Clozapine	<b>Tablet:</b> 25mg, 100mg,	S, T	Controlled	B
Conjugated Estrogen	<b>Topical Cream:</b> 0.625mg/g,	S, T	POM	B
Conjugated Estrogen	<b>Tablet:</b> 0.625mg	S, T	POM	B
Cyclophosphamide	<b>Tablet:</b> 25 mg; 50 mg	S, T	POM	B
Cyclosporin	<b>Capsule:</b> 25 mg	S, T	POM	B
Danazol	<b>Tablet:</b> 100 mg; 200 mg	S, T	POM	B
Desmopressin	Nasal spray: 10 mcg/spray	S, T	POM	B
Desmopressin	<b>Tablet:</b> 0.1 mg	S, T	POM	B
Digoxin	<b>Tablet:</b> 62.5 microgram; 250 micrograms	S, T	POM	B
Erythromycin <small>watch group antibiotic</small>	Capsule or <b>Tablet:</b> 250mg (as stearate or ethyl succinate);	S, T	POM	B
Erythromycin <small>watch group antibiotic</small>	Powder for oral suspension: 125 mg (as stearate or ethyl succinate)/5ml;	S, T	POM	B
Erythromycin <small>watch group antibiotic</small>	Powder for injection: 500 mg (as lactobionate) in vial	S, T	POM	B
Finasteride	<b>Tablet:</b> 1 mg; 5 mg	S, T	POM	B
Fludrocortisone	<b>Tablet:</b> 0.1 mg	S, T	POM	B
Flunarizine	<b>Tablet:</b> 5 mg; 10mg	S, T	POM	B
Flupentixol	<b>Tablet:</b> 0.5mg	S, T	POM	B
Folinic acid/leucovorin	<b>Tablet:</b> 5 mg; 10mg	S, T	POM	B
HiB vaccine		S, T	POM	B
Human Chorionic Gonadotrophin	<b>Injection:</b> 5000 IU; 10 000 IU in vial	S, T	POM	B
Human milk fortifier	Sachets	S, T	POM	B
Influenza vaccine [inactivated]		S, T	POM	B
Itraconazole	<b>Tablet:</b> 100 mg; 200 mg	S, T	POM	B
Labetalol	<b>Tablet:</b> 100 mg; 200mg; 300 mg	S, T	POM	B
Lamotrigine	<b>Tablet:</b> 25mg, 100mg	S, T	POM	B
Latanoprost	<b>Eye drop:</b> 0. 05 % (50mcg/ml)	S, T	POM	B
Levetiracetam	<b>Tablet:</b> 500mg	S, T	POM	B
Levetiracetam	<b>Syrup:</b> 100mg/mL	S, T	POM	B
Levodopa + Carbidopa	<b>Tablet:</b> 100 mg + 10mg	S, T	POM	B
Levonorgestrel	<b>Implant:</b> 150mg	S, T	POM	B
Lithium	<b>Tablet:</b> 300mg, 450mg	S, T	POM	B
Medroxyprogesterone	<b>Tablet:</b> 2.5 mg; 10mg	S, T	POM	B
Medroxyprogesterone acetate	Depot <b>Injection:</b> 150 mg/mL in 1 mL vial [intramuscular]	S, T	POM	B
Medroxyprogesterone acetate	<b>Tablet:</b> 100mg	S, T	POM	B
Memantine	<b>Tablet:</b> 5mg, 10mg	S, T	POM	B
Methotrexate	<b>Tablet:</b> 2.5 mg; 5 mg	S, T	POM	B
Methyldopa	<b>Tablet:</b> 250 mg; 500 mg	S, T	POM	B
Methylprednisolone	<b>Injection:</b> 20 mg/mL; 40 mg/mL; 80 mg/mL	S, T	POM	B
Midazolam	<b>Nasal spray:</b> 5 mg/0.1 mL	S, T	Controlled	B
Midazolam	<b>Tablet:</b> 7.5.mg	S, T	Controlled	B
Midazolam	<b>Syrup:</b> 2 mg/mL	S, T	Controlled	B
Moxifloxacin	<b>Eye drop</b>	S, T	POM	B
Neostigmine	<b>Tablet:</b> 15 mg [bromide]	S, T	POM	B
Nifedipine	Capsule/ <b>Tablet:</b> 10mg; retard 10mg; 20 mg	S, T	POM	B
Nitro-glycerine	<b>Ointment:</b> 0.2 %,	S, T	POM	B
Nitro-glycerine	<b>Injection:</b> 25mg/5ml	S, T	POM	B
Nystatin	<b>Lozenges:</b> 100 000 IU,	S, T	POM	B
Nystatin	<b>Pessary:</b> 100 000 IU	S, T	POM	B
Nystatin	<b>Tablet:</b> 100 000 IU; 500 000 IU	S, T	POM	B
Nystatin	<b>Syrup:</b> 100000 IU/ml	S, T	POM	B
Olanzapine	<b>Tablet:</b> 2.5.mg; 5 mg 10mg	S, T	Controlled	B
Oxybutynin	<b>Tablet:</b> 2.5mg, 5mg	S, T	POM	B
Phenylephrine	<b>Solution/eye drop:</b> 2.5 %	S, T	POM	B
Pilocarpine	<b>Solution [eye drop]:</b> 2 %; 4 % [HCl or nitrate]	S, T	POM	B
Pneumococcal conjugated vaccine		S, T	POM	B

Pneumococcal polysaccharide vaccine		S, T	POM	B
Podophyllum resin	<b>Solution:</b> 10 %; 25 %	S, T	POM	B
Prazosin	<b>Tablet:</b> 2mg	S, T	POM	B
Propylthiouracil	<b>Tablet:</b> 50mg	S, T	POM	B
Pyridostigmine	<b>Tablet:</b> 60 mg [bromide]	S, T	POM	B
Pyrimethamine	<b>Tablet:</b> 25 mg	S, T	POM	B
Quetiapine	<b>Tablet:</b> 25mg; 50mg; 100mg; 300mg	S, T	POM	B
Risperidone	<b>Depot Injection:</b> 25mg/vial, 50mg/vial	S, T	POM	B
Salicylic acid	<b>Solution:</b> 17%	S, T	POM	B
Salicylic acid	<b>Ointment:</b> 20 %	S, T	POM	B
Sulfasalazine	<b>Tablet:</b> 500 mg	S, T	POM	B
Sulphadiazine	<b>Tablet:</b> 500 mg	Sp	POM	B
Tacrolimus	<b>Eye ointment:</b> 0.3 %	S, T	POM	B
Tamoxifen	<b>Tablet:</b> 10mg; 20 mg [as citrate]	S, T	POM	B
Tamsulosin	<b>Capsule:</b> 0.4mg	S, T	POM	B
Testosterone	<b>Capsule:</b> 40 mg	S, T	POM	B
Tetracaine	<b>Eye drop [solution]:</b> 0.5 % [HCl]	S, T	Restricted for Health Facilities	B
Thiamine	<b>Tablet:</b> 50mg, 75 mg	S, T	POM	B
Ticagrelor	<b>Tablet:</b> 90mg, 180mg	S, T	POM	B
Topiramate	<b>Tablet:</b> 25 mg; 50 mg	S, T	POM	B
Alprazolam	<b>Tablet:</b> 0.25mg, 0.5mg	P, S, T	Controlled	B, E
Anti D Immunoglobulin [human]	<b>Injection:</b> 300 micrograms in single dose vial	S, T	POM	B, E
Cefazolin <small>access group antibiotic</small>	<b>Injection:</b> 500mg ;1gm	S, T	POM	B, E
Cefotaxime <small>watch group antibiotic</small>	<b>Injection:</b> 250mg; 500 mg; 1g	S, T	POM	B, E
Ceftazidime <small>watch group antibiotic</small>	Powder for injection: 250mg (as pentahydrate) in vial	S, T	POM	B, E
Ceftriaxone <small>watch group antibiotic</small>	<b>Injection:</b> 250 mg; 1 g	S, T	POM	B, E
Ciprofloxacin <small>watch group antibiotic</small>	<b>Injection:</b> 200mg/100ml (2mg/ml),	S, T	POM	B, E
Deferasirox	<b>Tablet:</b> 125 mg; 250 mg; 500	S, T	POM	B, E
Deferiprone	<b>Tablet:</b> 500 mg	S, T	POM	B, E
Desferrioxamine (Deferoxamine)	<b>Injection:</b> 500 mcg/mL [mesylate] in ampoule	S, T	POM	B, E
Enoxaparin	<b>Injection:</b> 40 mg [equivalent to 4000 IU]; 60mg [equivalent to 6000 IU]	S, T	POM	B, E
Erythropoietin	<b>Injection:</b> 2000 IU/0,5 mL	S, T	POM	B, E
Fentanyl	<b>Oral Liquid:</b> 2 mg/5 mL	S, T	Controlled	B, E
Fentanyl	<b>Tablet:</b> 2 mg; 5 mg	S, T	Controlled	B, E
Glucagon	<b>Injection:</b> 1 mg/mL	S, T	Restricted for Health Facilities	B, E
Glucose with sodium chloride	Injectable solution: 4 % glucose, 0.18 % sodium chloride [equivalent to Na+30mmol/L, Cl- 30 mmol/L]	P, S, T	POM	B, E
Meropenem <small>watch group</small>	Powder for injection: 500 mg (as trihydrate); 1 g (as trihydrate) in vial	T	POM	B, E
Midazolam	<b>Injection:</b> 1 mg/mL, 5 mg/mL in 2 mL ampoule	S, T	Controlled	B, E
Piperacillin + Tazobactam <small>watch group</small>	<b>Injection:</b> 2.25g, 4.5g	S, T	Restricted for Health Facilities	B, E
Zoledronate	<b>Injection:</b> 4mg/5mL, 5mg	S, T	POM	B, E
Barium sulphate	Aqueous suspension/powder	T	POM	C
Bicalutamide	<b>Tablet:</b> 50mg	T	POM	C
Bupropion	<b>Tablet:</b> 75 mg 150mg (ER)	T	POM	C
Cabergoline	<b>Tablet:</b> 0.25mg	T	POM	C
Capecitabine	<b>Tablet:</b> 500mg	T	POM	C
Carboplatin	<b>Tablet:</b> 150mg, 500mg	T	POM	C
Clomipramine	<b>Tablet/Capsule:</b> 10mg; 25 mg	T	POM	C
Cyclopentolate	<b>Eye drop:</b> 1 %	T	POM	C
Dasatinib	<b>Tablet:</b> 20mg, 50mg, 70mg, 80mg	T	POM	C
Donepezil	<b>Tablet:</b> 5mg, 10mg	T	POM	C
Etoposide	<b>Capsule:</b> 50mg, 100mg	T	POM	C
Fluvoxamine	<b>Tablet:</b> 25mg, 50mg, 100mg	T	POM	C
Hydroxychloroquine phosphate	<b>Tablet:</b> 200 mg	T	POM	C
Hydroxypropyl methyl cellulose	<b>Solution:</b> 2 %	T	OTC	C
Hydroxyurea	<b>Tablet:</b> 200 mg; 300 mg	T	POM	C
Ibrutinib	<b>Capsule:</b> 140mg	T	POM	C

Imatinib	<b>Tablet:</b> 100 mg; 400 mg	T	POM	C
Lenvatinib	<b>Capsule:</b> 4mg, 8mg, 10mg	T	POM	C
Letrozole	<b>Tablet:</b> 2.5mg	T	POM	C
Micronized progesterone	<b>Tablet:</b> 25mg;75 mg; 100 mg; 200 mg	T	POM	C
Naltrexone	<b>Tablet:</b> 50 mg	T	Controlled	C
Rivaroxabn	<b>Tablet:</b> 20mg	T	POM	C
Sildenafil	<b>Tablet:</b> 20 mg	T	POM	C
Sildenafil	<b>Syrup:</b> 10mg	T	POM	C
Sodium chloride	<b>Solution:</b> 5 %	T	POM	C
Sulphadoxine + pyrimethamine	<b>Tablet:</b> 500 mg + 25 mg	T	POM	C
Sumatriptan	<b>Tablet:</b> 25 mg; 50 mg	T	POM	C
Temozolomide	<b>Capsule:</b> 5mg, 20mg, 100mg	T	POM	C
Tranexamic acid	<b>Tablet:</b> 100 mg; 500 mg	T	POM	C
Varicella immunoglobulin [VZIG]	<b>Injection</b>	T	POM	C
Varicella vaccine	<b>Injection</b>	T	POM	C
Venlafaxine	<b>Tablet:</b> 25mg, 37.5mg, 75mg	T	POM	C
Acetylcysteine	<b>Injection:</b> 200 mg/ml in 10 mL – ampoule	P, S, T	Restricted for Health Facilities	D
Adrenaline (Epinephrine)	<b>Injection:</b> 1 mg/mL [1 in 1000], 0.5 mg/mL [1 in 10000]	P, S, T	Restricted for Health Facilities	D
Adrenaline (Epinephrine)	0.15mg, 0.30mg Auto injector	P, S, T	POM	D
Anti Tetanus immunoglobulin [human]	<b>Injection:</b> 250 IU; 500 IU S in vial	P, S, T	Restricted for Health Facilities	D
Atropine	<b>Injection:</b> 0.6 mg in 1 mL ampoule, 1mg (sulphate) in 1ml ampoule	P, S, T	Restricted for Health Facilities	D
Azathioprine	Powder for <b>Injection:</b> 100 mg [sodium salt] in vial	S, T	POM	D
Benzathine benzylpenicillin <small>access group</small>	Powder for injection: 1.44 g benzylpenicillin (=2.4 million IU), in 5-ml vial; 1.2million IU	P, S, T	Restricted for Health Facilities	D
Blood	Whole blood and pack cells	P, S, T	Restricted for Health Facilities	D
Bupivacaine	<b>Injection:</b> 0.25 %, 0.5 % [HCl] in vial.	P, S, T	Restricted for Health Facilities	D
Calcium gluconate	<b>Injection:</b> 100 mg/mL in 10 mL ampoule	P, S, T	Restricted for Health Facilities	D
Chloramphenicol <small>access group antibiotic</small>	Powder for <b>Injection:</b> 1 gram sodium succinate in vial	P, S, T	Restricted for Health Facilities	D
Dextran	<b>Injectable solution:</b> Dextran 40	P, S, T	Restricted for Health Facilities	D
Dopamine	<b>Injection:</b> 40 mg [HCl] in 5 ml vial	P, S, T	Restricted for Health Facilities	D
Epinephrine [adrenaline]	<b>Injection:</b> 1 mg [ as HCl or hydrogen tartrate] in 1 mL ampoule	P, S, T	Restricted for Health Facilities	D
Fluconazole	<b>Injection:</b> 2mg/mL in vial	P, S, T	Restricted for Health Facilities	D
Fluorescein	<b>Strips:</b> 0.6mg	P, S, T	Restricted for Health Facilities	D
Medical air	<b>Inhalation</b> (medical gas)	P, S, T	Restricted for Health Facilities	D
Methotrexate	<b>Powder for Injection:</b> 50mg	S, T	Restricted for Health Facilities	D
Oxytocin	<b>Injection:</b> 5 IU; 10 IU in 1 mL ampoule	P, S, T	Restricted for Health Facilities	D
Pethidine	<b>Injection:</b> 50 mg/mL [ HCl]	P, S, T	CONTROLLED	D
Phytomenadione [vitamin K1]	<b>Injection:</b> 10mg/mL in 5 mL ampoule	P, S, T	Restricted for Health Facilities	D
Potassium chloride	Injectable solution: 11.2 % in 20 ml ampoule [equivalent to K+1,5 mmol/L, Cl- 30 mmol/L]	S, T	Restricted for Health Facilities	D
Potassium chloride	Solution for dilution: 7.5 % [equivalent to K+1 mmol/L, 15 % [equivalent to K+ 2mmol/L, Cl-2mmol/L]	S, T	Restricted for Health Facilities	D
Streptokinase	<b>Powder for injection:</b> 1.5 million IU in vial	P, S, T	Restricted for Health Facilities	D
Tramadol	<b>Injection:</b> 50 mg/mL	P, S, T	Controlled	D
Trihexyphenidyl HCl	<b>Injection:</b> 5mg (lactate) in mL ampoule	P, S, T	Restricted for Health Facilities	D
Valproic acid (Sodium Valproate)	<b>Injection:</b> 100 mg/mL	P, S, T	Restricted for Health Facilities	D
Verapamil	<b>Injection:</b> 2.5mg [HCl]/mL in 2 mL ampoule	P, S, T	Restricted for Health Facilities	D
Fentanyl	<b>Injection:</b> 50 mcg/mL in 2–mL ampoule	S, T	Controlled	E
Albumin	<b>Injection:</b> 5 %; 10 %	S, T	Restricted for Health Facilities	E
Alteplase	<b>Injection:</b> 20 mg; 30 mg; 50 mg	S, T	Restricted for Health Facilities	E
Amidotrizoate	<b>Injection:</b> 140 mg – 420 mg iodine [as sodium or meglumine salt]/mL in 20 MI 24 ampoule	S, T	Restricted for Health Facilities	E

Aminophylline	<b>Injection:</b> 25 mg/mL in 10 mL ampoule	S, T	Restricted for Health Facilities	E
Antivenom Immunoglobulin	<b>Injection</b>	S, T	Restricted for Health Facilities	E
Atracurium	<b>Injection:</b> 10 m/mL [besylate]	S, T	Restricted for Health Facilities	E
Bupivacaine	<b>Injection for spinal anaesthesia:</b> 0.5 % [HCl] in a 4 mL ampoule to be mixed with 7.5 % glucose solution.	S, T	Restricted for Health Facilities	E
Caffeine citrate	<b>Injection:</b> 10mg/ml	S, T	Restricted for Health Facilities	E
Calcium Polystyrene Sulfonate	15 g Sachet	S, T	POM	E
Chloral hydrate	<b>Syrup:</b> 250 mg/5mL	S, T	Restricted for Health Facilities	E
Chlordiazepoxide	<b>Tablet:</b> 10mg	S, T	Controlled	E
Copper containing device	IUCD [ Copper T 380]	S, T	Restricted for Health Facilities	E
Cyclophosphamide	<b>Powder for Injection:</b> 500mg, 1000mg	S, T	Restricted for Health Facilities	E
Cyclophosphamide	<b>Injection:</b> 500mg/2.5mL	S, T	Restricted for Health Facilities	E
Cyclosporin	Concentrate for <b>Injection:</b> 50 mg/mL in 1 mL ampoule	S, T	Restricted for Health Facilities	E
Dantrolene sodium	<b>Injection:</b> 20 mg	S, T	Restricted for Health Facilities	E
Denosumab	<b>Injection:</b> 60mg/vial	S, T	Restricted for Health Facilities	E
Desmopressin	<b>Injection:</b> 4 mcg/mL	S, T	Restricted for Health Facilities	E
Diatrizoate Meglumine + Diatrizoate Sodium	Rectal and oral solution: 660 mg diatrizoate meglumine + 100 mg diatrizoate sodium/mL	S, T	Restricted for Health Facilities	E
Digoxin	<b>Injection:</b> 250 micrograms/mL in 2mL ampoule	S, T	Restricted for Health Facilities	E
Digoxin	<b>Oral liquid:</b> 50 microgram/mL	S, T	Restricted for Health Facilities	E
Diltiazem	<b>Injection:</b> 25 mg/5mL	S, T	POM	E
Ephedrine	<b>Injection:</b> 30 mg/ml [HCl] in 1 mL ampoule	S, T	Controlled	E
Ergometrine	<b>Injection:</b> 200 mcg [hydrogen maleate] in 1 mL ampoule	S, T	Restricted for Health Facilities	E
Esmolol	<b>Injection:</b> 10 mg/mL	S, T	Restricted for Health Facilities	E
Ethinylestradiol + cypoterone acetate	<b>Tablet:</b> 35 mcg + 2 mg [21 tablet packs]	S, T	POM	E
Etonogestrel-releasing implant	Implant containing 68 mg	S, T	Restricted for Health Facilities	E
Flumazenil	<b>Injection:</b> 100mcg /mL	S, T	Restricted for Health Facilities	E
Folinic acid/leucovorin	<b>Injection:</b> 10mg/ml, 50mg/ml	S, T	Restricted for Health Facilities	E
Fresh frozen plasma [FPP]	<b>Injection</b>	S, T	Restricted for Health Facilities	E
Gadolinium containing contrast for MRI	<b>Injection:</b> 287 mg/ML	S, T	Restricted for Health Facilities	E
Haemodialysis concentrate for parenteral solution		S, T	Restricted for Health Facilities	E
Halothane	<b>Inhalation.</b>	S, T	Restricted for Health Facilities	E
Human normal immunoglobulin	Intramuscular administration: 16 % protein solution	S, T	Restricted for Health Facilities	E
Human normal immunoglobulin	Intravenous administration: 5 %; 10 % solution	S, T	Restricted for Health Facilities	E
Hydralazine	<b>Injection:</b> 20 mg/mL [HCl] in ampoule	S, T	Restricted for Health Facilities	E
Intra lipid for total parenteral nutrition	Solution: 20 % {TPN}	S, T	Restricted for Health Facilities	E
Iohexol	<b>Injection:</b> 140 – 350 mg iodine/ML in 5 ML, 10 ML and 20 ML ampoule	S, T	Restricted for Health Facilities	E
Isoflurane	<b>Inhalation.</b>	S, T	Restricted for Health Facilities	E
Isoprenaline [isopropyl adrenaline]	<b>Injection:</b> 2 mg [HCl]/mL in an ampoule	S, T	Restricted for Health Facilities	E
Ketamine	<b>Injection:</b> 50mg/mL in 10 mL vial; 10mg/mL	S, T	Controlled	E
Labetalol	<b>Injection:</b> 5 mg/mL	S, T	Restricted for Health Facilities	E
Levetiracetam	<b>Injection:</b> 5mg/ml, 10mg/ml in 100ml	S, T	Restricted for Health Facilities	E
Lidocaine	Topical solution 4 %	S, T	Restricted for Health Facilities	E
Lidocaine	<b>Injection for spinal anaesthesia:</b> 5% [HCl] in a 2 mL ampoule to be mixed with 7.5 % glucose	S, T	Restricted for Health Facilities	E
Lidocaine	<b>Injection:</b> 1%, 2% (HCl) in vial	S, T	Restricted for Health Facilities	E
Lidocaine	<b>Topical forms:</b> 2% – 4 % [ HCl]; 10 % topical spray	S, T	Restricted for Health Facilities	E
Lidocaine + epinephrine [adrenaline]	<b>Injection:</b> 1 %, 2 % (HCl) + epinephrine 1:200 000 in a vial.	S, T	Restricted for Health Facilities	E

Lidocaine + epinephrine [adrenaline]	<b>Dental cartridge:</b> 2 % [HCl] + epinephrine 1:80,000.	S, T	Restricted for Health Facilities	E
Magnesium sulphate	<b>Injection:</b> 500mg/mL in 10mL ampoule, 250 mg/mL in 5 mL ampoule	S, T	Restricted for Health Facilities	E
Methotrexate	<b>Injection:</b> 50mg/2mL, 250mg/10mL	S, T	Restricted for Health Facilities	E
Methylene blue (methylthioninium chloride)	<b>Injection:</b> 10mg/mL in 10mL ampoule	S, T	Restricted for Health Facilities	E
Methylphenidate	<b>Capsule/ER Table:</b> 5mg,10mg,20mg, 25mg	S, T	Controlled	E
Mifepristone	<b>Tablet:</b> 200 mg	S, T	Restricted for Health Facilities	E
Misoprostol	<b>Tablet:</b> 25 mcg; 50 mcg; 100mcg ; 200 mcg	S, T	Restricted for Health Facilities	E
Morphine	<b>Oral liquid:</b> 10mg [HCl or sulphate]/5 mL	S, T	Controlled	E
Morphine	<b>Tablet:</b> 5mg; 10mg; 15mg; 30mg modified release [sulphate]	S, T	Controlled	E
Morphine	<b>Injection:</b> 10mg [sulphate of HCl] in 1 mL ampoule.	S, T	Controlled	E
Neostigmine	<b>Injection:</b> 500 mcg in 1 mL ampoule;	S, T	Restricted for Health Facilities	E
Neostigmine	250 mcg in 1 mL ampoule [methyl sulphate]	S, T	Restricted for Health Facilities	E
Nitrous oxide	<b>Inhalation.</b>	S, T	Restricted for Health Facilities	E
Olanzapine	Depot Injection: 210mg/vial, 300mg/vial, 405mg/vial	S, T	Controlled	E
Peritoneal dialysis solution		S, T	Restricted for Health Facilities	E
PG F 2 alpha [Carboprost],	<b>Injection:</b> 250 mcg	S, T	Restricted for Health Facilities	E
Platelet concentrate		S, T	Restricted for Health Facilities	E
Procaine benzylpenicillin <sup>access group</sup> antibiotic	<b>Injection:</b> 1.2 million IU	S, T	Restricted for Health Facilities	E
Propofol	<b>Injection:</b> 10mg/mL, 20 mg/mL	S, T	Restricted for Health Facilities	E
Prostaglandins	Prostaglandin E2: 1 mg/mL;	S, T	Restricted for Health Facilities	E
Prostaglandins	Prostaglandin E1: 0.5 mg/mL	S, T	Restricted for Health Facilities	E
Protamine Sulfate	<b>Injection:</b> 10mg/mL in 5 mL ampoule	S, T	POM	E
Pyridostigmine	<b>Injection:</b> 1 mg in 1 mL ampoule	S, T	Restricted for Health Facilities	E
Rocuronium	<b>Injection:</b> 50 mg/5 mL	S, T	Restricted for Health Facilities	E
Sodium Nitrite	<b>Injection:</b> 30 mg/mL in 10 mL ampoule	S, T	POM	E
Surfactant	Suspension for intra-tracheal instillation: 25mg/mL; 80 mg/mL	S, T	POM	E
Suxamethonium	<b>Injection:</b> 50mg [Chloride]/mL in 2 mL ampoule	S, T	POM	E
Tenecteplase	<b>Injection:</b> 30mg, 40mg, 50mg	S, T	Restricted for Health Facilities	E
Testosterone	<b>Injection:</b> 100 mg/mL; 200 mg/mL [enanthate] in 1 mL ampoule	S, T	Restricted for Health Facilities	E
Thiamine	<b>Injection:</b> 100 mg	S, T	Restricted for Health Facilities	E
Tuberculin Purified Protein Derivative [PPD]	<b>Injection:</b> 5 IU; 10 IU	S, T	Restricted for Health Facilities	E
Visco elastic	<b>Pre-filled syringe:</b> 2%	S, T	Restricted for Health Facilities	E
Abiraterone	<b>Tablet:</b> 500 mg	T	POM	F
Adriamycin	<b>Injection:</b> 50 mg/25 ml	T	Restricted for Health Facilities	F
Amino acid	<b>Infant solution:</b> 10 %	T	Restricted for Health Facilities	F
Amphotericin B	<b>Injection:</b> 50mg/vial (Lypholized), (as sodium deoxycholate or liposomal complex).	T	Restricted for Health Facilities	F
Bleomycin	<b>Powder for Injection:</b> 15000 IU (as sulfate) in vial	T	Restricted for Health Facilities	F
Bortezomib	<b>Powder for Injection:</b> 3.5mg in a vial	T	Restricted for Health Facilities	F
Cisplatin	<b>Injection:</b> 10mg/10mL, 20mg/20mL, 50mg/50mL	T	Restricted for Health Facilities	F
Colistin <sup>Reserve group</sup>	Powder <b>Injection:</b> 1 million unit I.U in vial	T	Restricted for Health Facilities	F
Cytarabine	<b>Injection:</b> 100mg/1ml, 500mg/5ml	T	Restricted for Health Facilities	F
Dacarbazine	<b>Powder for Injection:</b> 100mg, 200mg in a vial	T	Restricted for Health Facilities	F
Etoposide	<b>Injection:</b> 20mg/mL in 5 mL ampoule	T	Restricted for Health Facilities	F
Etoposide	<b>Powder for Injection:</b> 100mg (as phosphate) in vial	T	Restricted for Health Facilities	F
Factor IX concentrate	<b>Injection:</b> 500 IU/mL	T	Restricted for Health Facilities	F

Factor VIII concentrate	<b>Injection:</b> 500 IU/mL	T	Restricted for Health Facilities	F
Filgrastim	<b>Injection:</b> 120 mcg/0.2mL, 300mcg/0.5mL, 480mcg/0.8mL in pre-filled syringe	T	Restricted for Health Facilities	F
Fluorouracil	<b>Injection:</b> 50mg/mL in a vial	T	Restricted for Health Facilities	F
Gemcitabine	<b>Powder for Injection:</b> 200mg, 1g in a vial	T	Restricted for Health Facilities	F
Hepatitis B Immunoglobulin [HBIG]	<b>Injection:</b> 200 iU/mL	T	Restricted for Health Facilities	F
Ifosfamide	<b>Powder for Injection:</b> 500mg, 1g in a vial	T	Restricted for Health Facilities	F
Irinotecan	<b>Injection:</b> 40mg/2mL in 2mL vial, 100mg/5mL in 5mL vial, 500mg/25mL in 25mL vial.	T	Restricted for Health Facilities	F
Iron (Parenteral)	<b>Injection:</b> 50mg iron/mL (Dextran/Sucrose)	T	Restricted for Health Facilities	F
IV immunoglobulin [IVIG]	<b>Injection:</b> 2.5 g/vial; 5 g/vial; 10 g/vial	T	Restricted for Health Facilities	F
Lidocaine for intracameral use	<b>Injection:</b> 1%	T	Restricted for Health Facilities	F
Linezolid <small>Reserve group</small>	<b>Injection:</b> 2 mg/ml, Tablets: 400mg, 600 mg, Powder for oral liquid 100 mg/5 ml	T	Restricted for Health Facilities	F
Moxifloxacin for intracameral use	<b>Injection:</b> 150mcg/0.1 mL	T	Restricted for Health Facilities	F
Naloxone	<b>Injection:</b> 400 mcg [HCl] in 1 mL ampoule	P, S, T	Controlled (Restricted for use of National Drug Agency - NDA only)	F
Octreotide	<b>Depot:</b> 10mg, 20mg	T	Restricted for Health Facilities	F
Oxaliplatin	<b>Injection:</b> 50mg/10mL in 10mL vial, 100mg/20mL in 20mL vial	T	Restricted for Health Facilities	F
Paclitaxel	<b>Injection:</b> 6mg/mL in a vial	T	Restricted for Health Facilities	F
Ranibizumab	<b>Injection:</b> 10mg/ml	T	Restricted for Health Facilities	F
Rituximab	<b>Injection:</b> 10mg/mL	T	Restricted for Health Facilities	F
Sodium hydrogen carbonate	<b>Injectable solution:</b> 1.4% isotonic [equivalent to Na+167 mmol/L; HCO <sup>-</sup> 167 mmol/L	T	Restricted for Health Facilities	F
Sodium nitroprusside	<b>Injection:</b> 50 mg/5mL in ampoule	T	POM	F
Tranexamic acid	<b>Injection:</b> 100 mg/mL in 10 mL – ampoule	T	Restricted for Health Facilities	F
Trastuzumab	<b>Powder for Injection:</b> 60mg, 150mg, 440mg in vial	T	Restricted for Health Facilities	F
Trypan Blue	<b>Solution:</b> 0.06%	T	Restricted for Health Facilities	F
Vancomycin <small>watch group</small>	<b>Powder for injection:</b> 250mg; 500 mg in vial	T	Restricted for Health Facilities	F
Vinblastine	<b>Injection:</b> 1mg/ml (1ml)	T	Restricted for Health Facilities	F
Vincristine	<b>Injection:</b> 1mg/mL (sulfate); 2mg/2mL (sulfate) in vial	T	Restricted for Health Facilities	F
Buprenorphine	<b>Tablet:</b> 2 mg, 4 mg	T	Controlled (Restricted for use of National Drug Agency - NDA only)	F
Methadone [HCl]	Concentrate for <b>Oral liquid:</b> 5 mg/mL; 10mg/mL	T	Controlled (Restricted for use of National Drug Agency - NDA only)	F
Human papilloma virus [HPV] vaccine		NP	Restricted and to be used for the National program only	NP
Abacavir [ABC]	<b>Oral liquid:</b> 100 mg/5mL [as sulphate]	NP	Restricted and to be used for the National program only	NP
Abacavir [ABC]	<b>Tablet:</b> 300 mg [as sulphate]	NP	Restricted and to be used for the National program only	NP
Artemether	<b>Tablet:</b> 80 mg	NP	Restricted and to be used for the National program only	NP
Artemether	<b>Injection:</b> 80 mg/mL in 1 mL ampoule	NP	Restricted and to be used for the National program only	NP
Artemether + lumefantrine	<b>Tablet:</b> 20 mg + 120 mg	NP	Restricted and to be used for the National program only	NP
Artesunate	<b>Tablet:</b> 150 mg	NP	Restricted and to be used for the National program only	NP
Artesunate	Rectal dosage form/ <b>Capsule:</b> 50 mg; 100 mg; 200 mg	NP	Restricted and to be used for the National program only	NP

Artesunate	<b>Injection:</b> 150mg in vials	NP	Restricted and to be used for the National program only	NP
Artesunate + mefloquine	<b>Tablet:</b> 25 mg + 55 mg, 100 mg + 220 mg	NP	Restricted and to be used for the National program only	NP
BCG vaccine		Np	Restricted and to be used for the National program only	NP
Chloroquine	<b>Tablet:</b> 150 mg	NP	Restricted and to be used for the National program only	NP
Cholera vaccine		NP	Restricted and to be used for the National program only	NP
Clofazimine	<b>Capsule:</b> 50 mg; 100 mg	NP	Restricted and to be used for the National program only	NP
Corona virus Covid 19 vaccine		NP	Restricted and to be used for the National program only	NP
Cycloserine	Tablet or <b>Capsule:</b> 250 mg	NP	Restricted and to be used for the National program only	NP
Dapsone	<b>Tablet:</b> 25 mg; 50 mg; 100 mg	NP	Restricted and to be used for the National program only	NP
Dataclavir	<b>Tablet:</b> 90 mg	NP	Restricted and to be used for the National program only	NP
Diethylcarbamazine	<b>Tablet:</b> 50 mg; 100 mg	NP	Restricted and to be used for the National program only	NP
Diphtheria + Tetanus		NP	Restricted and to be used for the National program only	NP
Diphtheria antitoxin	<b>Injection:</b> 10 000 IU; 20 000 IU in vial	NP	Restricted and to be used for the National program only	NP
Diphtheria, pertussis and tetanus vaccine		NP	Restricted and to be used for the National program only	NP
Diphtheria-Tetanus-Pertussis [whole cell] – Hepatitis B – Haemophilus influenza type b		NP	Restricted and to be used for the National program only	NP
Efavirenz [EFV or EFZ]	<b>Capsule:</b> 50 mg; 100 mg; 200 mg	NP	Restricted and to be used for the National program only	NP
Efavirenz [EFV or EFZ]	<b>Oral liquid:</b> 150 mg/5mL	NP	Restricted and to be used for the National program only	NP
Efavirenz [EFV or EFZ]	<b>Tablet:</b> 600 mg	NP	Restricted and to be used for the National program only	NP
Efavirenz + Emtricitabine + Tenofovir	<b>Tablet:</b> 600 mg + 200 mg + 300 mg	NP	Restricted and to be used for the National program only	NP
Emtricitabine + Rilpivirine + Tenofovir	<b>Tablet:</b> 600 mg + 300 mg + 200 mg;	NP	Restricted and to be used for the National program only	NP
Emtricitabine + Rilpivirine + Tenofovir	200 mg+ 300 mg + 600 mg	NP	Restricted and to be used for the National program only	NP
Emtricitabine + Tenofovir	<b>Tablet:</b> 200 mg + 300 mg	NP	Restricted and to be used for the National program only	NP
Entecavir	<b>Tablet:</b> 0.5 mg; 1 mg	NP	Restricted and to be used for the National program only	NP
Ethambutol	<b>Tablet:</b> 100 mg; 400 mg; 600 mg	NP	Restricted and to be used for the National program only	NP
Ethionamide	<b>Tablet:</b> 125 mg; 250 mg	NP	Restricted and to be used for the National program only	NP
Hepatitis A vaccine		NP	Restricted and to be used for the National program only	NP
Hepatitis B vaccine		NP	Restricted and to be used for the National program only	NP
Isoniazid	<b>Tablet:</b> 100 mg; 300 mg; tablet [scored]50 mg	NP	Restricted and to be used for the National program only	NP
Kanamycin	Powder for <b>Injection:</b> 1 g in vial	NP	Restricted and to be used for the National program only	NP
Lamivudine [3TC]	<b>Oral liquid:</b> 50 mg/5 mL	NP	Restricted and to be used for the National program only	NP
Lamivudine [3TC]	<b>Tablet:</b> 150 mg	NP	Restricted and to be used for the National program only	NP
Lepidasvir + Sofosbuvir [for hepatitis C]	<b>Tablet:</b> 90 mg + 400 mg	NP	Restricted and to be used for the National program only	NP
Levonorgestrel	IUD containing 52 mg	NP	Restricted and to be used for the National program only	NP



Lopinavir + Ritonavir [LPV/R]	<b>Capsule:</b> 133.3 mg + 33.3 mg	NP	Restricted and to be used for the National program only	NP
Lopinavir + Ritonavir [LPV/R]	<b>Oral liquid:</b> 400 mg + 100 mg/5 mL	NP	Restricted and to be used for the National program only	NP
Lynesterol	<b>Tablet:</b> 0.5mg	NP	Restricted and to be used for the National program only	NP
Measles + rubella		NP	Restricted and to be used for the National program only	NP
Measles vaccine		NP	Restricted and to be used for the National program only	NP
Measles, mumps, rubella vaccines		NP	Restricted and to be used for the National program only	NP
Mefloquine	<b>Tablet:</b> 250 mg	NP	Restricted and to be used for the National program only	NP
Meningococcal meningitis vaccine		NP	Restricted and to be used for the National program only	NP
Nelfinavir [NFV]	<b>Tablet:</b> 250mgas mesylate	NP	Restricted and to be used for the National program only	NP
Nelfinavir [NFV]	<b>Oral Powder:</b> 50 mg/g	NP	Restricted and to be used for the National program only	NP
Nevirapine [NVP]	<b>Oral liquid:</b> 50 mg/5mL	NP	Restricted and to be used for the National program only	NP
Nevirapine [NVP]	<b>Tablet:</b> 200 mg	NP	Restricted and to be used for the National program only	NP
Poliomyelitis [oral] vaccine		NP	Restricted and to be used for the National program only	NP
Primaquine	<b>Tablet:</b> 7.5 mg; 15 mg	NP	Restricted and to be used for the National program only	NP
Proguanil	<b>Tablet:</b> 100 mg	NP	Restricted and to be used for the National program only	NP
Pyrazinamide	<b>Tablet:</b> 400 mg; 500 mg; 750 mg; 1000 mg	NP	Restricted and to be used for the National program only	NP
Pyridoxine	<b>Tablet:</b> 50mg; 40mg, 10mg	NP	Restricted and to be used for the National program only	NP
Quinine	<b>Tablet:</b> 100 mg; 300 mg	NP	Restricted and to be used for the National program only	NP
Quinine	<b>Injection:</b> 300 mg/mL in 2 mL ampoule	NP	Restricted and to be used for the National program only	NP
Retinol	Sugar coated <b>Tablet:</b> 10 000 IU [palmitate, 5.5mg];	NP	Restricted and to be used for the National program only	NP
Retinol	<b>Capsule:</b> 200 000 IU [palmitate, 110mg]	NP	Restricted and to be used for the National program only	NP
Retinol	Oral oily solution: 100 000 IU [palmitate]/mL in multidose dispenser	NP	Restricted and to be used for the National program only	NP
Retinol	Water miscible <b>Injection:</b> 100 000 IU [palmitate, 55 mg] in 2 mL ampoule	NP	Restricted and to be used for the National program only	NP
Ribavarin [for hepatitis C]	<b>Capsule:</b> 200 mg	NP	Restricted and to be used for the National program only	NP
Rifampicin	<b>Tablet/Capsule:</b> 150 mg; 300 mg	NP	Restricted and to be used for the National program only	NP
Rifampicin	<b>Syrup:</b> 100 mg/5mL; 200 mg/5mL	NP	Restricted and to be used for the National program only	NP
Rifampicin + Isoniazid	<b>Tablet/Capsule:</b> 150mg+ 75 mg; 300 mg + 150 mg; 60 mg +30 mg; 75 mg + 50 mg; 60 mg + 60 mg	NP	Restricted and to be used for the National program only	NP
Rifampicin + Isoniazid + Ethambutol	<b>Tablet/Capsule:</b> 150mg+ 75mg + 275mg	NP	Restricted and to be used for the National program only	NP
Rifampicin + Isoniazid + Pyrazinamide + Ethambutol	<b>Tablet/Capsule:</b> 150mg + 75mg + 400mg + 275mg	NP	Restricted and to be used for the National program only	NP
Ritonavir	<b>Oral liquid:</b> 400 mg/5 mL	NP	Restricted and to be used for the National program only	NP
Ritonavir	<b>Capsule or Tablet:</b> 100 mg	NP	Restricted and to be used for the National program only	NP
Sofosbuvir [ for hepatitis C]	<b>Tablet:</b> 400 mg	NP	Restricted and to be used for the National program only	NP
Streptomycin	<b>Powder for Injection:</b> 1 g in vial [sulphate]	NP	Restricted for Health Facilities	NP
Td vaccine		NP	Restricted for Health Facilities	NP

Tenofovir [Hepatitis B]	<b>Tablet:</b> 300 mg	NP	Restricted and to be used for the National program only	NP
Tenofovir + Emtricitabine	<b>Tablet:</b> 300 mg + 200 mg	NP	Restricted and to be used for the National program only	NP
Tenofovir disoproxil fumarate [TDF]	<b>Tablet:</b> 300 mg [Tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil]	NP	Restricted and to be used for the National program only	NP
Typhoid vaccine		NP	Restricted and to be used for the National program only	NP
Yellow fever vaccine		NP	Restricted and to be used for the National program only	NP
Zidovudine [ZDV or AZT]	<b>Capsule:</b> 100 mg; 250 mg	NP	Restricted and to be used for the National program only	NP
Zidovudine [ZDV or AZT]	<b>Tablet:</b> 100 mg; 300 m	NP	Restricted and to be used for the National program only	NP
Zidovudine [ZDV or AZT]	<b>Oral liquid:</b> 50 mg/5mL	NP	Restricted and to be used for the National program only	NP
Zidovudine [ZDV or AZT]	<b>Solution for IV infusion:</b> 10mg/mL in 20 mL vial	NP	Restricted and to be used for the National program only	NP
Zidovudine + Lamivudine	<b>Tablet:</b> 300 mg + 150 mg	NP	Restricted and to be used for the National program only	NP
Zidovudine + Lamivudine + Nevirapine	<b>Tablet:</b> 300 mg + 150mg+ 200 mg	NP	Restricted and to be used for the National program only	NP